<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Recent Drugs Mini Test - -Tmt - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / NEET PG Mini Test Series / 2023-24
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">20</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>function _0x5804(){const _0x365eb9=['RSEDH','zVTSA','cmbbm','yUnff','console','<p>The\x20correct\x20match\x20is:</p>\x0a<table\x20style=\x22height:\x20185px;\x22\x20width=\x22357\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20170.667px;\x22><strong>Biological\x20therapy</strong></td>\x0a<td\x20style=\x22width:\x20170.667px;\x22><strong>Target\x20Site</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20170.667px;\x22>A.\x20Deucravacitinib</td>\x0a<td\x20style=\x22width:\x20170.667px;\x22>3.\x20TYK-2&nbsp;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20170.667px;\x22>B.\x20Brodalumab</td>\x0a<td\x20style=\x22width:\x20170.667px;\x22>4.\x20IL-17</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20170.667px;\x22>C.\x20Etanercept</td>\x0a<td\x20style=\x22width:\x20170.667px;\x22>1.\x20TNF‐&alpha;</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20170.667px;\x22>D.\x20Ustekinumab&nbsp;</td>\x0a<td\x20style=\x22width:\x20170.667px;\x22>2.\x20IL-12/23</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Psoriasis</strong>\x20is\x20a\x20group\x20of\x20common\x20<strong>chronic\x20inflammatory\x20and\x20proliferative\x20conditions</strong>\x20of\x20the\x20skin,\x20associated\x20with\x20systemic\x20manifestations\x20in\x20many\x20organ\x20systems.\x20The\x20most\x20characteristic\x20lesions\x20consist\x20of<strong>\x20red,\x20scaly,\x20sharply\x20demarcated,\x20indurated\x20plaques,\x20present\x20particularly\x20over\x20the\x20extensor\x20surfaces\x20and\x20scalp.</strong></p>\x0a<p><strong>Biological\x20treatments</strong>\x20are\x20part\x20of\x20<strong>Systemic\x20therapy</strong>\x20for\x20Psoriasis.\x20They\x20are\x20newer\x20and\x20well-established\x20for\x20managing\x20moderate\x20to\x20severe\x20psoriasis.</p>\x0a<p><strong>Deucravacitinib\x20</strong>is\x20a\x20<strong>Tyrosine\x20kinase\x202\x20(TYK2)\x20inhibitor</strong>\x20indicated\x20for\x20the\x20treatment\x20of\x20adults\x20with\x20moderate-to-severe\x20plaque\x20psoriasis\x20who\x20are\x20candidates\x20for\x20systemic\x20therapy\x20or\x20phototherapy.\x20It\x20has\x20been\x20recently\x20approved\x20by\x20FDA.\x20The\x20most\x20common\x20adverse\x20reactions\x20associated\x20with\x20Deucravacitinib\x20are\x20<strong>upper\x20respiratory\x20infections,\x20blood\x20creatine\x20phosphokinase\x20increased,\x20herpes\x20simplex,</strong>\x20mouth\x20ulcers,\x20folliculitis,\x20and\x20acne.&nbsp;</p>\x0a<p><strong>Ustekinumab</strong>\x20is\x20a\x20fully\x20human\x20IgG1&nbsp;\x20monoclonal\x20antibody\x20<strong>against\x20the\x20p40\x20subunit\x20</strong>that\x20is\x20common\x20to\x20both\x20<strong>IL‐12\x20and\x20IL‐23.</strong>\x20It\x20is\x20indicated\x20in\x20patients\x20with\x20moderate\x20to\x20severe\x20psoriasis.\x20<strong>Dizziness,\x20sore\x20throat\x20</strong>and\x20joint\x20pain\x20are\x20the\x20most\x20common\x20side\x20effects\x20associated\x20with\x20Ustekinumab.&nbsp;</p>\x0a<p><strong>Brodalumab</strong>\x20is\x20a\x20fully\x20<strong>human\x20IL‐17RA\x20monoclonal\x20antibody</strong>\x20used\x20in\x20the\x20management\x20of\x20moderate\x20to\x20severe\x20psoriasis.\x20It\x20leads\x20to\x20<strong>black\x20tarry\x20stools,\x20lethargy\x20and</strong>\x20joint\x20pain\x20as\x20the\x20most\x20common\x20adverse\x20effects.</p>\x0a<p><strong>Etanercept</strong>\x20is\x20a\x20fully\x20human\x20soluble\x20TNF‐&alpha;\x20receptor\x20fusion\x20protein\x20that\x20binds\x20and\x20neutralizes\x20<strong>TNF‐&alpha;</strong>,\x20in\x20psoriasis.\x20<strong>Hypersensitivity</strong>\x20is\x20the\x20most\x20notable\x20and\x20severe\x20adverse\x20effect\x20seen\x20with\x20Etanercept.</p>','kFKfP','ZifHL','Hepatocellular\x20Carcinoma','umTUf','tKkwK','{}.constructor(\x22return\x20this\x22)(\x20)','Fwmlh','tqDQM','bQuQQ','mNXoS','DzxeZ','Bookmarked','wXFqG','eAgNl','Insulin','userHistory','nGbjY','wVBwm','G6PD\x20deficiency','Futibatinib,\x20a\x20newly\x20approved\x20drug\x20is\x20used\x20in\x20the\x20treatment\x20of\x20metastasis\x20of\x20which\x20of\x20the\x20following\x20tumors?','bYBMX','markedForReview','spOTz','totalQuestions','disabled','UltaE','open','woFqp','none','TqPqp','As\x20a\x20MRI\x20contrast\x20agent','studyModeLegend','appendChild','AKVCi','Silver\x20sulfadiazine','<p>The\x20given\x20scenario\x20of\x20a\x20man\x20with\x20<strong>hemolytic\x20anaemia,</strong>\x20treated\x20with\x20<strong>Mitapivat</strong>\x20suggests\x20the\x20diagnosis\x20of\x20<strong>Pyruvate\x20kinase\x20deficiency.</strong></p>\x0a<p>The\x20mature\x20erythrocyte\u00a0lacks\x20mitochondria\x20and\x20is\x20completely\u00a0dependent\x20on\x20glycolysis\x20to\x20produce\x20ATP.\x20<strong>Pyruvate\x20kinase</strong>\x20is\x20an\x20enzyme\x20required\x20for\x20the\x20process\x20of\x20<strong>glycolysis</strong>.\x20In\x20cases\x20of\x20<strong>pyruvate\x20kinase\x20deficiency</strong>,\x20the\x20anaemia\x20observed\x20is\x20a\x20consequence\x20of\x20the\x20<strong>reduced\x20rate<span\x20class=\x22Apple-converted-space\x22>\u00a0o</span><span\x20class=\x22Apple-converted-space\x22>f</span><span\x20class=\x22Apple-converted-space\x22>\u00a0</span>glycolysis</strong>,\x20leading\x20to\u00a0<strong>decreased\x20ATP\x20</strong>production.\x20This\x20leads\x20to\x20<strong>alterations</strong>\u00a0in\x20the\x20red\x20blood\x20cell\u00a0<strong>membrane\x20</strong>causing\x20changes\x20in\x20the\x20cell\x27s\x20shape\x20and\x20later\x20phagocytosis\x20by\x20the\x20cells\x20of\x20the\x20reticuloendothelial\x20system.\x20This\x20premature\x20death\x20and\x20lysis\x20of\x20the\x20red\x20blood\x20cell\x20result\x20in\x20hemolytic\x20anaemia.\x20It\x20occurs\x20more\x20frequently\x20in\x20i<strong>nfants\x20and\x20newborns</strong>,\x20but\x20cases\x20can\x20also\x20present\x20in\x20<strong>adulthood</strong>.</p>\x0a<p><strong>Mitapivat</strong>\x20is\x20a\x20recently\x20approved\x20oral\x20drug\x20which\x20is\x20a\x20<strong>pyruvate\x20kinase\x20activator</strong>\x20indicated\x20for\x20the\x20treatment\x20of\x20<strong>hemolytic\x20anaemia\x20</strong>in\x20adults\x20with\x20<strong>pyruvate\x20kinase\x20(PK)\x20deficiency</strong>.\x20It\x20allosterically\x20binds\x20to\x20the\x20pyruvate\x20kinase\x20tetramer\x20and\x20increases\x20pyruvate\x20kinase\x20(PK)\x20activity.\x20The\x20most\x20common\x20<strong>adverse\x20reactions</strong>\x20are\x20<strong>back\x20pain,\x20arthralgia,\x20decreased\x20estrone\x20and\x20estradiol\x20</strong>(in\x20males)\x20and<strong>\x20increased\x20urate\x20levels.</strong></p>\x0a<p>The\x20<strong>severe\x20form</strong>\x20of\x20the\x20disease\x20requires\x20regular\x20packed\x20red\x20cell\u00a0<strong>transfusion\u00a0</strong>with<strong>\u00a0iron\u00a0chelation\u00a0</strong>and<strong>\u00a0folic\u00a0acid\u00a0supplementation.</strong></p>\x0a<p>Other\x20options:\x20Option\x20A\x20-\x20<strong>Glucose\x206\x20Phosphatase\x20Dehydrogenase(G6PD)</strong>\x20is\x20an\x20enzyme\x20of\x20the\x20Hexose\x20monophosphate\x20pathway.\x20G6PD\x20deficiency\x20also\x20causes\x20<strong>Hemolytic\x20anaemia</strong>\x20but\x20it\x20is\x20not\x20treated\x20with\x20Mitapivat.</p>\x0a<p>Option\x20C-<strong>\x205\x27\x20Nucleotidase\x20deficiency</strong>\x20also\x20leads\x20to\x20<strong>hemolytic\x20anaemia</strong>.\x20The\x20hallmark\x20of\x20this\x20enzyme\x20deficiency\x20is\x20the\x20presence\x20of\x20pronounced\u00a0basophilic\x20stippling\u00a0and\u00a0accumulation\x20of\x20pyrimidine\x20nucleotides\u00a0(RNA\u00a0remnants)\x20within\x20erythrocytes.\x20Mitapivat\x20is\x20not\x20used\x20for\x20treatment.</p>\x0a<p>Option\x20D\x20-\x20The\x20deficiency\x20of<strong>\x20Aspartoacylase</strong>\x20leads\x20to\u00a0<strong>Canavan\x20disease</strong>.\x20It\x20is\x20an\x20autosomal-recessive\x20disorder,\x20which\x20leads\x20to\x20excessive\x20excretion\x20of\x20N-acetyl\x20aspartic\x20acid\x20in\x20the\x20urine.\x20It\x20is\x20characterized\x20by\x20leukodystrophy\x20and\x20does\x20not\x20cause\x20hemolysis.</p>','uKFFp','explanation_audio_hin','AWAdx','MnmTE','timed_study','FqsOR','incorrectCount','createElement','MRWIi','exception','FUnyp','AoqeJ','Anemia\x20in\x20CKD\x20patients','ETPZI','xXelm','answered','<p><strong>Pegunigalsidase\x20alfa</strong>\x20or\x20simply\x20<strong>Pegunigalsidase\x20</strong>is\x20a\x20newly\x20approved\x20drug\x20by\x20the\x20FDA\x20used\x20for\x20treating\u00a0<strong>adults</strong>\x20with<strong>\x20Fabry\x20Disease.</strong></p>\x0a<p><strong>Fabry\x20disease</strong>\x20is\x20caused\x20due\x20to\x20<strong>alpha-galactosidase\x20deficiency\u00a0</strong>leading\x20to\x20the\x20accumulation\x20of\x20globotriaosyl-ceramide.\x20It\x20is\x20an\x20X-linked\x20recessive\x20disorder,\x20hence\x20full\x20symptoms\x20are\x20only\x20seen\x20in\x20males.\x20They\x20usually\x20present\x20as\x20<strong>skin\x20rashes\x20</strong>and<strong>\x20kidney\x20failure</strong>.\x20Treatment\x20is\x20with\u00a0<strong>enzyme\x20replacement\x20therapy</strong>\x20(recombinant\x20alpha-Gal\x20A\x20or\x20migalastat).\x20Recently\x20The\x20FDA\x20approved\x20<strong>Pegunigalsidase\u00a0</strong>for\x20treating\x20confirmed\x20cases\x20of\x20Fabry\x20Disease.</p>\x0a<p><strong>Pegunigalsidase</strong>\x20is\x20a\x20modified\x20<strong>recombinant\x20human\x20alpha-galactosidase\x20A\x20enzyme</strong>.\x20In\x20patients\x20with\x20Fabry\x20disease,\x20it\x20acts\x20as\x20an\x20exogenous\x20source\x20of\x20alpha-galactosidase\x20A.\x20The\x20most\x20common\x20adverse\x20reactions\x20are\x20infusion-associated\x20reactions(\x20and\x20hypersensitivity),\x20nasopharyngitis,\x20headache,\x20diarrhea,\x20fatigue,\x20nausea,\x20back\x20pain,\x20and\x20sinusitis.</p>\x0a<p>Other\x20options:\x20Option\x20A\x20-\x20<strong>Tay-Sachs</strong>\x20disease\x20is\x20caused\x20due\x20to\x20hexosaminidase\x20A\x20deficiency\x20leading\x20to\x20the\x20accumulation\x20of\x20Glucocerebroside.\x20Clinical\x20symptoms\x20include\x20mental\x20retardation,\x20blindness,\x20and\x20muscular\x20weakness.\u00a0</p>\x0a<p>Option\x20C-\x20<strong>Gaucher\x20Disease</strong>\x20is\x20a\x20genetic\x20disorder\x20due\x20to\x20glucocerebrosidase\x20(β-glucosidase)\x20deficiency<strong>.</strong>\x20Patients\x20present\x20with\x20hepatosplenomegaly,\x20pancytopenia,\x20osteoporosis,\x20and\x20avascular\x20necrosis\x20of\x20the\x20femur.\x20<strong>Imiglucerase\u00a0</strong>is\x20used\x20as\x20enzyme\x20replacement\x20therapy.</p>\x0a<p>Option\x20D\x20-\x20<strong>Niemann-Pick</strong>\x20disease\u00a0is\x20caused\x20due\x20to\x20sphingomyelinase\x20deficiency\u00a0leading\x20to\x20the\x20accumulation\x20of\x20sphingomyelin.\x20Clinical\x20features\x20include\x20mental\x20retardation\x20and\x20hepatosplenomegaly.</p>','explanation_audio_eng','ttVll','CkALC','qRNZB','JJIqf','prototype','jSOkq','solutionContainer','qjwaz','RuSez','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','pathname','UBmcg','RGXQE','ArrowRight','solutionText','WEtFo','now','question_video','text','questions','toggle','LIsVW','querySelectorAll','QyPFZ','round','A-3,\x20B-4,\x20C-2,\x20D-1','vxTLY','jJxJI','LpqNV','Not\x20Attempted','stats','dstbY','HcHtF','yhvcF','ADmSQ','dASxx','A-2,\x20B-4,\x20C-1,\x20D-3','twwGk','FcAXt','Omaveloxolone','UKjTH','remove','ZJnpW','aTsQp','izoJk','HmVTi','OwozJ','NKGrN','zCvOx','kJWdn','HXBhp','flex','ecgFE','cMWBZ','LAbBr','bjYWL','<p><strong>Daridorexant</strong>\x20is\x20an\x20<strong>Orexin\x20Antagonist</strong>\x20used\x20for\x20the\x20treatment\x20of\x20<strong>Insomnia</strong>.</p>\x0a<p><strong>Insomnia</strong>\x20is\x20defined\x20as\x20<strong>difficulty\x20initiating\x20or\x20maintaining\x20sleep.\x20</strong>It\x20may\x20be\x20transient\x20or\x20persistent.\x20<strong>Daridorexant</strong>\x20is\x20an\x20<strong>orexin\x20receptor\x20antagonist</strong>\x20indicated\x20for\x20<strong>treating</strong>\x20adult\x20patients\x20with\x20<strong>insomnia</strong>\x20characterized\x20by\x20difficulties\x20with\x20sleep\x20onset\x20or\x20sleep\x20maintenance.\x20The\x20orexin\x20neuropeptide\x20signalling\x20system\x20plays\x20a\x20role\x20in\x20wakefulness.\x20Daridorexant\x20<strong>blocks\x20the\x20binding\x20of</strong>\x20wake-promoting\x20neuropeptides\x20<strong>orexin\x20A\x20and\x20orexin\x20B\x20to\x20their\x20receptors</strong>\x20suppressing\x20the\x20wake\x20drive.\x20It\x20is\x20an\x20<strong>oral</strong>\x20preparation\x20and\x20the\x20most\x20common\x20<strong>adverse\x20effects</strong>\x20are\x20<strong>headache</strong>\x20and\x20<strong>somnolence</strong>\x20or\x20fatigue.\x20<strong>Suvorexant</strong>\x20is\x20also\x20an\x20<strong>Orexin\x20Receptor\x20antagonist</strong>\x20used\x20for\x20the\x20treatment\x20of\x20insomnia.</p>\x0a<p>Other\x20options:<strong>&nbsp;Melatonin\x20analogue\x20</strong><span\x20class=\x22fontstyle0\x22>approved\x20for\x20the\x20treatment\x20of&nbsp;<strong>insomnia\x20is\x20Ramelteon.</strong>\x20It\x20is\x20used\x20mainly\x20in\x20conditions\x20with\x20<strong>difficulties</strong>&nbsp;of<strong>&nbsp;sleep\x20onset</strong>.\x20<strong>Tasimelteon\x20and\x20Agomelatine</strong>\x20are\x20other\x20drugs\x20included\x20in\x20this\x20drug\x20class.</span></p>\x0a<p><span\x20class=\x22fontstyle0\x22>Hypocretin\x20neurons\x20activate\x20wake-promoting\x20pathways\x20in\x20the\x20CNS.\x20A\x20<strong>deficiency\x20of\x20hypocretin</strong>,\x20likely\x20due\x20to\x20autoimmune\x20destruction\x20of\x20hypocretin\x20neurons,\x20produces\x20<strong>narcolepsy</strong>,\x20a\x20condition\x20of\x20hypersomnia,\x20including\x20excessive\x20daytime\x20sleepiness\x20and\x20sudden\x20attacks\x20of\x20sleep.\x20<strong>Melatonin\x20antagonists\x20and\x20Orexin\x20agonists\x20are\x20not\x20used\x20in\x20humans\x20</strong>to\x20treat\x20narcolepsy.&nbsp;</span></p>\x0a<p><span\x20class=\x22fontstyle0\x22>Rather\x20<strong>CNS\x20stimulants</strong>,\x20which\x20enhance\x20transmission\x20in\x20monoamine\x20pathways\x20<strong>like\x20modafinil\x20and\x20armodafinil</strong>\x20are\x20used\x20in\x20the\x20<strong>treatment\x20of\x20Narcolepsy</strong>.</span></p>\x0a<p>&nbsp;</p>','svPok','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','yDscB','ZYwnb','WOgNO','questionNav','xXzLq','OHlpA','YkvCX','1195SvRazA','className','Betaxolol','pfgqk','setItem','HgDoe','QeLIA','.option-button','BfWbl','Mark\x20for\x20Review','zUPlw','PFuwR','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','QQOiK','lQsGO','2023-24','iTAsj','nmlqR','wimtI','includes','Paroxysmal\x20nocturnal\x20hemoglobinuria','ZanTy','xmmXa','kZhxg','qBErF','selected','IzIoU','Qplcj','Silver\x20nitrate','Pbrvz','Nirsevimab','parse','nMmXr','bookmarked','Perfluorohexyloctane\x20is\x20used\x20for:','AzpUg','nIHIB','A-3,\x20B-4,\x20C-1,\x20D-2','JkTbN','title','hKGRn','hidden','lXLjT','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','CRinG','quizPerformanceData','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','map','Ketoacidosis','question_images','147qgJuDA','BievT','FPKiO','add','explanationVideoPlayer','Latanoprost','WEwQy','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','error','rTDVf','ZPfor','bsNuS','SFTtD','qrecv','A\x2019-year-old\x20male\x20presents\x20with\x20a\x20staggering\x20gait\x20and\x20a\x20history\x20of\x20frequent\x20falls.\x20On\x20examination,\x20deep\x20tendon\x20reflexes\x20are\x20depressed\x20and\x20nystagmus\x20is\x20seen.\x20PCR\x20reveals\x20expansion\x20of\x20a\x20GAA\x20trinucleotide\x20repeat.\x20Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20for\x20the\x20treatment\x20of\x20this\x20patient?','reviewQuestionsContainer','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','NyTeo','textContent','VCUGg','push','Urinary\x20tract\x20infections','BcSxC','FknpN','correct','reduce','gnKLr','Marrow','ydyEM','Gout','A-3,\x20B-2,\x20C-4,\x20D-1','performanceModal','isArray','jzrpY','__proto__','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','GSDpx','RYDJL','pATCB','bind','getAttribute','incorrectAnswers','No\x20question\x20text\x20available','EpGUv','test','pFsXT','aBUcN','NPEck','lmEOK','video[data-src]','aStOF','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','Dorzolamide','pWlvV','Warm\x20antibody\x20autoimmune\x20hemolytic\x20anaemia','totalTime','sXfeO','Sutimlimab\x20is\x20used\x20in\x20the\x20treatment\x20of\x20which\x20of\x20the\x20given\x20conditions?','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','ilweM','zdKqY','oWGVv','PYXUJ','Brimonidine','log','hxsyi','vOZTa','223576tcEusl','wKhLz','Trofinetide','ELodh','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','resume','question_audio','Pyruvate\x20Kinase\x20deficiency','pehLQ','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','jEHvw','iLzaz','avgTimeResult','LPqrm','fIEJK','WELTP','Marked','kWvoc','WnZUa','vRqVq','PHLFh','AkARn','WqqnA','Intra-hepatic\x20Cholangio-carcinoma','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','20KvbKPo','wozmc','ziiNn','Zavegepant','\x22\x20data-option-index=\x22','pdtPf','endsWith','A-4,\x20B-3\x20C-2,\x20D-1','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','VubRP','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','<p><strong>Perfluorohexyloctane</strong>\x20is\x20used\x20for\x20the\x20treatment\x20of\x20<strong>dry\x20eye.&nbsp;</strong></p>\x0a<p><strong>Dry\x20eye\x20disease</strong>\x20occurs\x20due\x20to\x20inadequate\x20tear\x20volume\x20and\x20function,\x20resulting\x20In\x20<strong>unstable\x20tear\x20film</strong>\x20and\x20ocular\x20surface\x20disease.\x20Many\x20conditions\x20can\x20lead\x20to\x20dry\x20eye\x20including\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>Sjögren\x20syndrome,\x20</span><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>Vitamin\x20A\x20deficiency,\x20</span><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>Follicular\x20conjunctivitis,\x20Wearing\x20contact\x20lenses\x20and\x20Trachoma.\x20<strong>Tear\x20film\x20tests</strong>\x20(<strong>Schrimer\x27s\x20test,\x20Tear\x20film\x20break\x20up\x20test\x20</strong>and<strong>\x20Rose\x20Bengal\x20staining)</strong>\x20are\x20<strong>used\x20to\x20diagnose</strong>\x20Dry\x20eye\x20disease.</span></p>\x0a<p><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22><strong>Treatment&nbsp;</strong>for\x20dry\x20eye\x20includes\x20<strong>medical&nbsp;</strong>treatment\x20(lubricating\x20eyedrops,\x20most\x20commonly&nbsp;<strong>methylcellulose</strong>&nbsp;derivatives)\x20or&nbsp;<strong>surgical</strong>&nbsp;treatment\x20(lacrimal\x20punctum\x20occlusion\x20using&nbsp;<strong>silicone</strong>\x20plugs).\x20</span></p>\x0a<p><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>Recently\x20the\x20FDA\x20approved\x20<strong>Perfluorohexyloctane\x20</strong>as\x20an\x20ophthalmic\x20solution\x20for\x20treating\x20dry\x20eye.\x20It\x20is\x20used\x20as\x20<strong>eyedrops</strong>\x20to\x20be\x20instilled\x20<strong>four\x20times\x20a\x20day</strong>.\x20It\x20forms<strong>&nbsp;a\x20monolayer</strong>\x20at\x20the\x20<strong>tear\x20film\x27s\x20air-liquid\x20interface,</strong>\x20which\x20is\x20expected\x20<strong>to\x20reduce\x20evaporation</strong>.\x20The\x20most\x20common\x20<strong>adverse\x20effect</strong>\x20associated\x20with\x20the\x20use\x20of\x20Perflurohexyloctane\x20is\x20<strong>blurred\x20vision.</strong>&nbsp;\x20Rarely\x20it\x20can\x20lead\x20to\x20<strong>conjunctival\x20redness</strong>.</span></p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>','aCxZI','https://dhmbxeygs57ff.cloudfront.net/uploads/223d24b7e0d84721a94c23176114c9dax1280x2560.JPEG','src','ykTgL','TtbRY','currentQuestion','zhonR','questionMedia','xRYiV','href','hierarchy','Recent\x20Drugs\x20Mini\x20Test\x20-\x20-Tmt','wrZsU','ujnUl','markReviewBtn','border-red-500','edVvH','Pegunigalsidase,\x20a\x20newly\x20approved\x20drug\x20is\x20used\x20in\x20the\x20treatment\x20of\x20which\x20of\x20the\x20following\x20condition?','YEqRq','ucSXy','<p><strong>Bexagliflozin\x20</strong>is\x20a\x20recently\x20approved\x20drug\x20used\x20for\x20glycemic\x20control\x20in\x20patients\x20with\x20<strong>Type\x202\x20DM</strong>.\x20The\x20most\x20common\x20adverse\x20effect\x20associated\x20with\x20the\x20drug\x20is\x20<strong>Urinary\x20tract\x20infections</strong>.</p>\x0a<p><strong>Bexagliflozin</strong>\x20is\x20a\x20newly\x20approved\x20drug\x20by\x20the\x20FDA.\x20It\x20is\x20a\x20<strong>Sodium-glucose\x20co-transporter\x202\x20(SGLT2)\x20inhibitor</strong>\x20indicated\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20exercise\x20to\x20improve\x20glycemic\x20control\x20in\x20adults\x20with\x20type\x202\x20diabetes\x20mellitus.\x20Inhibiting\x20SGLT2\x20reduces\x20renal\x20reabsorption\x20of\x20filtered\x20glucose,\x20thereby\x20<strong>increasing</strong>\x20<strong>urinary\x20glucose\x20excretion</strong>.\x20This\x20increased\x20glucose\x20load\x20in\x20the\x20urine\x20increases\x20the\x20risk\x20of\x20<strong>urinary\x20and\x20genital\x20mycotic\x20</strong>infections.</p>\x0a<p>Other\x20<strong>adverse\x20effects</strong>\x20associated\x20with\x20the\x20use\x20of\x20<strong>Bexagliflozin&nbsp;</strong>are\x20<strong>Ketoacidosis</strong>(\x20In\x20patients\x20with\x20Type\x201\x20DM),\x20<strong>Lower</strong>\x20<strong>Limb</strong>\x20<strong>Amputation</strong>,\x20<strong>Volume\x20Depletion,\x20Hypoglycemia\x20</strong>(with\x20Concomitant\x20Use\x20with\x20Insulin)\x20and\x20<strong>Necrotizing\x20Fasciitis\x20of\x20the\x20Perineum\x20(Fournier&rsquo;s\x20Gangrene).</strong></p>\x0a<p>All\x20the\x20other\x20options\x20are\x20also\x20possible\x20adverse\x20effects\x20that\x20could\x20develop\x20after\x20using\x20Bexagliflozin\x20but\x20occur\x20less\x20frequently\x20than\x20Urinary\x20tract\x20infections.\x20If\x20used\x20in\x20patients\x20with\x20Type\x201\x20DM\x20<strong>Bexagliflozin\x20</strong>can\x20cause&nbsp;<strong>euglycemic\x20diabetic\x20ketoacidosis\x20(DKA)</strong>\x20because\x20of\x20the\x20increased\x20excretion\x20of\x20glucose\x20in\x20the\x20urine\x20which\x20induces\x20glucagon\x20secretion\x20which\x20in\x20turn\x20increases\x20the\x20production\x20of\x20glucose\x20and\x20ketones\x20in\x20the\x20liver\x20leading\x20to\x20ketoacidosis.</p>\x0a<p>It\x20also\x20<strong>increases\x20the\x20risk\x20of\x20fractures</strong>\x20and\x20<strong>lower\x20limb\x20amputations\x20</strong>due\x20to\x20the\x20creation\x20of\x20an\x20imbalance\x20with\x20the\x20minerals\x20and\x20circulating\x20parathormone\x20and\x20vitamin\x20D.</p>\x0a<p>Concomitant\x20use\x20of\x20<strong>Insulin</strong>\x20and\x20<strong>Bexagliflozin</strong>\x20may\x20lead\x20to\x20the\x20development\x20of\x20<strong>Hypoglycemia</strong>.</p>\x0a<p>&nbsp;</p>','(((.+)+)+)+$','style','CibtG','xkLdL','testModeLegend','UrVrz','solution','FxlVN','ZqHMg','study','FMaYe','qNgbW','recent-drugs-mini-test-tmt-93629c20.html','nav-btn-marked-review','return\x20(function()\x20','CLlLd','Lambert-Eaton\x20syndrome','ExzBR','htCsL','AoYte','fDxfi','IxSkq','SafGv','QaIMU','PSbxo','contains','tOpzF','vScmp','sjCbz','ZGmzt','XhbGT','GUEJT','As\x20a\x20treatment\x20for\x20dry\x20eye','QkSue','MIOTW','VZbFi','wcgnH','cHycG','YfidG','Given\x20below\x20are\x20a\x20few\x20Biological\x20therapies\x20used\x20in\x20the\x20management\x20of\x20Psoriasis.\x20Match\x20the\x20drugs\x20to\x20their\x20target\x20site\x20of\x20action.','<p><strong>Sutimlimab</strong>\x20is\x20used\x20in\x20the\x20treatment\x20of&nbsp;<strong>Cold\x20Agglutinin\x20disease.</strong></p>\x0a<p><strong>Cold\x20Agglutinin\x20disease&nbsp;</strong>is\x20a\x20type\x20of\x20immune\x20hemolytic\x20anaemia\x20which\x20is\x20<strong>caused\x20by\x20IgM\x20antibodies</strong>\x20that\x20bind\x20to\x20red\x20cells\x20avidly\x20at\x20<strong>low\x20temperatures</strong>\x20(0&deg;C\x20to\x204&deg;C)\x20but\x20not\x20at\x2037&deg;C,\x20resulting\x20in\x20vascular\x20obstruction\x20and\x20<strong>extravascular\x20hemolysis.\x20</strong>Cold\x20agglutinin\x20antibodies\x20sometimes\x20appear\x20transiently\x20<strong>following\x20certain\x20infections</strong>,\x20such\x20as\x20<strong><em>Mycoplasma\x20pneumoniae,</em></strong>\x20<em>Epstein-Barr\x20virus\x20</em>and<em>\x20CMV.</em></p>\x0a<p><strong>Clinically</strong>\x20it\x20presents\x20with<strong>&nbsp;pallor,\x20cyanosis,&nbsp;</strong>and\x20the<strong>\x20Raynaud\x20phenomenon\x20of\x20fingers,\x20toes\x20and\x20ears\x20</strong>when<strong>\x20</strong>exposed\x20to&nbsp;<strong>cold\x20temperatures&nbsp;</strong>of<strong>&nbsp;</strong>0&deg;\x20C\x20to\x204&deg;C.<strong>&nbsp;</strong>The\x20disorder\x20is\x20usually\x20self-limiting\x20but\x20<strong>Chronic\x20cold\x20agglutinin\x20immune\x20hemolytic\x20anaemia\x20</strong>which\x20may\x20occur\x20in\x20certain\x20<strong>B-cell\x20neoplasms</strong>\x20requires\x20treatment.\x20<strong>Sutimlimab&nbsp;</strong>is\x20one\x20of\x20the\x20newly\x20approved\x20drugs\x20which\x20can\x20be\x20used\x20to\x20manage\x20<strong>chronic\x20and\x20severe</strong>\x20<strong>Cold\x20Agglutinin\x20disease.</strong></p>\x0a<p><strong>Sutimlimabis</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20<strong>inhibits\x20the\x20classical\x20complement\x20pathway</strong>\x20by\x20binding\x20to\x20<strong>complement\x20protein\x20C1s</strong>\x20(s\x20subcomponent\x20of\x20C1)\x20thus\x20preventing<strong>&nbsp;the\x20deposition\x20of\x20</strong>complement\x20<strong>opsonins\x20on</strong>\x20the\x20surface\x20of\x20<strong>RBCs</strong>.\x20This\x20inhibits\x20hemolysis\x20in\x20patients\x20with\x20<strong>Cold\x20Agglutinin\x20disease.\x20</strong>The\x20most\x20common\x20<strong>adverse\x20reactions</strong>\x20associated\x20with\x20Sutimlimab\x20are\x20<strong>Respiratory\x20tract\x20infection</strong>,\x20<strong>diarrhoea</strong>,&nbsp;<strong>cough</strong>,\x20<strong>arthralgia</strong>\x20and\x20<strong>peripheral\x20oedema</strong>.&nbsp;</p>\x0a<p><strong>Warm\x20antibody</strong><strong>\x20immune\x20hemolytic\x20anaemia</strong>&nbsp;is\x20caused\x20by\x20<strong>antibodies</strong>\x20that\x20bind\x20to\x20Rbcs\x20<strong>at\x2037\x20degrees\x20Celsius</strong>.\x20It\x20may\x20be\x20idiopathic,\x20or\x20secondarily\x20caused\x20by&nbsp;<strong>drugs</strong>&nbsp;such\x20as&nbsp;<strong>alpha-methyldopa</strong>,\x20other&nbsp;<strong>autoimmune\x20diseases</strong>&nbsp;such\x20as\x20SLE,\x20or\x20lymphoid\x20neoplasms.&nbsp;</p>\x0a<p><strong>&nbsp;Paroxysmal\x20nocturnal\x20hemoglobinuria(PNH)</strong>\x20is\x20a\x20disease\x20that\x20results\x20from\x20<strong>acquired\x20mutations</strong>&nbsp;in\x20the&nbsp;<strong>phosphatidylinositol\x20glycan\x20complementation\x20group\x20A\x20gene</strong>\x20(PIGA).\x20It\x20is\x20chronic\x20<strong>hemolytic\x20anaemia</strong>\x20that\x20is\x20characterized\x20by\x20intravascular\x20hemolysis\x20causing\x20hemoglobinuria.\x20Apart\x20from\x20hemolysis,\x20other\x20features\x20like\x20<strong>pancytopenia</strong>\x20and\x20<strong>venous\x20thrombosis</strong>\x20are\x20also\x20seen.</p>\x0a<p><strong>Paroxysmal\x20cold\x20hemoglobinuria\x20(PCH</strong>)\x20is\x20a\x20<strong>cold\x20hemolysin\x20type&nbsp;</strong>of\x20hemolysis\x20caused\x20by<strong>&nbsp;IgG</strong>\x20autoantibodies\x20which\x20are\x20produced\x20often\x20in\x20response\x20to\x20a\x20viral\x20infection.\x20This\x20antibody\x20is\x20a&nbsp;<strong>biphasic\x20hemolysin.&nbsp;</strong>i.e.,\x20the\x20antibody\x20<strong>binds\x20to\x20RBC\x20at\x20colder\x20temperatures</strong>\x20but\x20<strong>hemolysis\x20occurs\x20at\x20a\x20core\x20temperature\x20of\x2037&deg;C\x20</strong>leading\x20to\x20intravascular\x20hemolysis\x20and\x20hemoglobinuria.\x20Most\x20cases\x20are\x20seen\x20in&nbsp;<strong>children</strong><strong>&nbsp;</strong>and\x20usually\x20recover\x20within\x201\x20month.</p>\x0a<p>&nbsp;</p>','CkoPm','BBrDn','A\x2020-year-old\x20boy\x20presents\x20to\x20you\x20following\x20the\x20burn\x20injury\x20as\x20shown\x20in\x20the\x20below\x20image.\x20Your\x20senior\x20consultant\x20advises\x20you\x20to\x20prescribe\x20a\x20topical\x20agent\x20that\x20can\x20remove\x20the\x20eschar.\x20Which\x20of\x20the\x20following\x20agents\x20is\x20best\x20suited\x20for\x20this\x20specific\x20purpose?','ukfQX','getItem','Niemann-Pick\x20disease','Omidenepag\x20has\x20been\x20recently\x20approved\x20for\x20the\x20treatment\x20of\x20Glaucoma.\x20Which\x20of\x20the\x20given\x20drugs\x20has\x20a\x20mechanism\x20of\x20action\x20most\x20similar\x20to\x20that\x20of\x20Omidenepag?','RpZDl','sSPhk','accuracy','Fabry\x20disease','mTJtN','toString','gUiWe','iVIKr','startAt','Correct','HJWZE','mrteU','Tofersen\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20which\x20of\x20the\x20following\x20conditions?','bBLWM','<p><strong>Nirsevimab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20recently\x20approved\x20by\x20the\x20FDA\x20to\x20be\x20used\x20as\x20a\x20<strong>prophylaxis</strong>\u00a0against\x20respiratory\x20syncytial\x20virus\x20(RSV)\x20infection.</p>\x0a<p><strong>RSV</strong>\u00a0is\x20responsible\x20for\x20more\x20than\x20half\x20of\x20the\x20cases\x20of\u00a0<strong>bronchiolitis</strong>\u00a0in\u00a0<strong>infants</strong>\u00a0<strong>less\x20than\x201\x20year</strong>\x20of\x20age.\x20It\x20generally\x20presents\x20as\x20a\x20fever\x20with\x20cough\x20and\x20wheezing.\x20It\x20has\x20a\x20very\x20high\x20infectivity\x20and\x20transmission\x20is\x20by\x20close\x20contact\x20and\x20droplet\x20transmission.\x20Nasopharyngeal\x20swabs\x20and\x20nasal\x20washings\x20are\x20collected\x20as\x20samples.\x20They\x20are\x20inoculated\x20in\x20cell\x20culture\x20(HeLa\x20or\x20Hep-2)\x20immediately\x20after\x20collection.\x20In\x20cultured\x20cells,\x20RSV\x20shows\x20characteristic\x20<strong>giant\x20cells</strong>\u00a0and<strong>\x20syncytial\x20formation.</strong></p>\x0a<p>The\x20image\x20given\x20below\x20shows\x20<strong>giant\x20cells</strong>\x20and\u00a0<strong>syncytial\x20formation</strong>\u00a0seen\x20in\x20<strong>RSV\x20infection:</strong></p>','yjIfv','Lower\x20limb\x20amputaion','7739748hgOHWa','RlELx','oGhaZ','statsBar','raSfI','LMZVS','sfXwo','solutionAudio','canPlayType','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','hIgTr','VNCIK','strokeDasharray','ZrgUO','JkGfg','MiAaj','caqDy','referrer','Endometrial\x20Carcinoma','get','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','trSgh','Option\x20','9047742avvzFK','preventDefault','LjKfw','5|3|1|4|2|0','Cold\x20Agglutinin\x20disease','Lewy\x20body\x20dementia','ArrowLeft','rgSEC','bAfXf','dDbus','MqwbC','Incorrect','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','yZibx','SJRWJ','RDmtP','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','floor','NvJDY','.m3u8','Malignant\x20Melanoma','border-green-500','rABfF','choices','DvKsK','attachMedia','iWthH','constructor','XWREk','isSupported','<p><strong>Daprodustat\x20</strong>is\x20a\x20newly\x20approved\x20drug\x20by\x20the\x20FDA\x20used\x20for\x20treating\x20<strong>Anemia\x20in\x20CKD\x20patients.</strong></p>\x0a<p>In\x20patients\x20with\x20<strong>CKD</strong>(Chronic\x20Kidney\x20Disease),\x20there\x20is\x20<strong>decreased\x20erythropoietin\x20</strong>production\x20which\x20in\x20turn\x20leads\x20to\x20the\x20development\x20of\x20Anemia.</p>\x0a<p><strong>Daprodustat</strong>\x20is\x20a\x20reversible\x20<strong>inhibitor\x20of\x20HIF-PH</strong>(Hypoxia-inducible\x20factor–prolyl\x20hydroxylase\x20domain).\x20This\x20activity\x20results\x20in\x20the\x20stabilization\x20and\x20nuclear\x20<strong>accumulation\x20of\x20HIF\x20transcription\x20factors</strong>,\x20leading\x20to\x20increased\x20<strong>transcription\x20of\x20the\x20HIF-responsive\x20genes,</strong>\x20including\x20<strong>erythropoietin</strong>\x20and\x20thereby\x20correcting\x20Anemia.\x20However,\x20an\u00a0optimal\x20response\x20to\x20treatment\x20with\x20Daprodustat\x20occurs\x20only\x20when\x20<strong>iron\x20stores</strong>\u00a0are\u00a0<strong>adequate</strong>\x20to\x20complement\x20the\x20increased\x20erythropoietin\x20levels\x20for\x20producing\x20new\x20RBCs.<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>It\x20is\x20reserved\x20for\x20Patients\x20who\x20have\x20been\x20receiving\x20<strong>dialysis\x20for\x20at\x20least\x20four\x20months.</strong></span></p>\x0a<p>Daprodustat\x20is\x20given\x20as\x20<strong>once-daily\x20oral\x20preparation.</strong>\x20The\x20most\x20common\x20<strong>adverse\x20reactions\x20</strong>are<strong>\x20hypertension,\x20thrombotic\x20vascular\x20events,\x20</strong>and<strong>\x20abdominal\x20pain.\x20</strong>It\x20increases\x20the\x20risk\x20of\x20thrombotic\x20vascular\x20events,\x20including\x20major\x20adverse\x20cardiovascular\x20events\x20like\x20<strong>myocardial\x20infarction,\x20stroke\x20</strong>and<strong>\x20venous\x20thromboembolism.</strong></p>\x0a<p>\u00a0</p>','apply','correct_choice_id','KrOiu','incomplete','svWGZ','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','tFBDN','questionStates','DOMContentLoaded','totalQuestionsResult','UgqHh','rDVKV','gaOMH','stringify','BdjcM','PHvfQ','UdFeg','correctAnswers','tHIuw','loadSource','oBAjc','DCmOa','PUxzu','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','yldTe','SorVK','not_attempted','QlJxV','div','<div\x20class=\x22mt-4\x22><img\x20src=\x22','GkjRn','Eflapegrastim\x20belongs\x20to\x20which\x20of\x20the\x20given\x20drug\x20class?','wWVJn','JDnZm','custom_quiz.html','A\x20man\x20who\x20presented\x20with\x20features\x20of\x20anemia\x20was\x20treated\x20with\x20Mitapivat\x20after\x20lab\x20investigations.\x20Which\x20condition\x20is\x20he\x20likely\x20to\x20be\x20suffering\x20from?','padStart','Amyotrophic\x20Lateral\x20Sclerosis','quizSidebar','\x20-\x20Brain\x20And\x20Scalpel','customQuizData','-600\x20text-white\x22>','Anacaulase','currentQuestionIndex','quizHierarchy','zCHPO','3|0|1|2|5|4','eRuRP','incorrectResult','hnLTo','CnLxH','vPeEL','jfdkF','GhnvP','704HGJnyv','key','Teplizumab','OCCJM','wWMtG','timeSpent','currentMode','GLdIq','timed_exam','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','ekMDy','display','YUelE','innerHTML','BnBUp','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','block','length','nFCQy','mFcJt','rtLpg','fmnzV','NUjvv','wARyW','bookmarkBtn','location','LkZdZ','toLowerCase','Omalizumab','PcgdQ','QGKZZ','ewaes','<p><strong>Rezafungin</strong>\x20belongs\x20to\x20the\x20<strong>Echinocandin</strong>\x20group\x20of\x20drugs.\x20It\x20<strong>inhibits</strong>\x20the\x20activity\x20of\x20the\x20<strong>glucan\x20synthase\x20complex\x20</strong>marked\x20by\x20<strong>site\x204\x20</strong>in\x20the\x20image.</p>\x0a<p><strong>Rezafungin&nbsp;</strong>is\x20a\x20newly\x20FDA-approved\x20Echinocandin\x20antifungal\x20reserved\x20as\x20a\x20second-line\x20agent<strong>\x20for\x20treating\x20candidemia\x20and\x20invasive\x20candidiasis</strong>.\x201,3-&beta;-D\x20glucan\x20is\x20an\x20essential\x20component\x20of\x20the\x20fungal\x20cell\x20wall\x20which\x20maintains\x20cell\x20integrity.\x20Rezafungin\x20similar\x20to\x20other\x20Echinocandins&nbsp;acts\x20by&nbsp;<strong>inhibiting\x20the\x20synthesis\x20of&nbsp;1,3-&beta;-D-glucan</strong>\x20and\x20thereby\x20weakens\x20the\x20fungal\x20cell\x20wall\x20and\x20increases\x20the\x20osmotic\x20susceptibility\x20of\x20candida.\x20It\x20is\x20administered\x20<strong>intravenously</strong>\x20in\x20patients\x20at\x20least\x20<strong>18\x20years\x20old</strong>.\x20The\x20most\x20common\x20<strong>adverse\x20reactions</strong>\x20are\x20<strong>hypokalemia,\x20pyrexia,\x20diarrhoea,\x20anaemia,\x20vomiting,\x20abdominal\x20pain\x20</strong>and<strong>\x20constipation.</strong></p>\x0a<p>Site\x20of\x20action\x20of\x20other\x20Antifungal\x20agents:</p>','<div\x20class=\x22ng-scope\x22>\x0a<div\x20class=\x22ng-scope\x22>\x0a<p><strong>Omidenepag\x20</strong>is\x20a\x20<strong>Prostaglandin-E\x20receptor\x20agonist</strong>.\x20Amongst\x20the\x20given\x20options,\x20its\x20mechanism\x20of\x20action\x20is\x20most\x20similar\x20to\x20<strong>Latanoprost</strong>,\x20a\x20<strong>Prostaglandin-F\x20receptor\x20agonist</strong>.</p>\x0a<p><strong>Omidenepag</strong>\x20is\x20a\x20relatively\x20selective\x20PG-E2(Prostaglandin\x20E2)\x20receptor\x20agonist\x20which\x20decreases\x20intraocular\x20pressure\x20(IOP)\x20by\x20<strong>increasing\x20uveoscleral\x20outflow\x20</strong>from\x20the\x20anterior\x20chamber\x20of\x20the\x20eye.\x20In\x20this\x20way,\x20it\x20acts\x20similarly\x20to\x20<strong>Latanoprost</strong>,\x20a\x20selective\x20PGF2-alpha\x20receptor\x20agonist\x20that\x20reduces\x20IOP\x20by<strong>\x20increasing\x20uveoscleral\x20outflow</strong>.\x20Both\x20of\x20these\x20drugs\x20are\x20classified\x20as\x20<strong>Prostaglandin\x20Receptor\x20agonists</strong>(Prostaglandin\x20analogues).</p>\x0a<p>Similar\x20to\x20latanoprost\x20the\x20<strong>adverse\x20effects</strong>\x20include\x20<strong>iris\x20pigmentation,\x20eyelash\x20changes,\x20ocular\x20Inflammation</strong>\x20and\x20<strong>macular\x20edema</strong>.\x20It\x20may\x20also\x20lead\x20to\x20<strong>conjunctival\x20hyperemia,\x20photophobia\x20and\x20blurred\x20vision.</strong></p>\x0a<p>Other\x20options:\x20<strong>Brimonidine\x20</strong>is\x20a\x20<strong>selective\x20alpha\x20agonist\x20</strong>used\x20in\x20glaucoma.\x20It\x20acts\x20mainly\x20by\x20<strong>decreasing\x20the\x20aqueous\x20production</strong>\x20and\x20thus\x20lowering\x20the\x20IOP.</p>\x0a<p><strong>Betaxolol</strong>\x20is\x20a\x20<strong>selective</strong>\x20<strong>beta\x201\x20blocker\x20</strong>that\x20is\x20used\x20in\x20glaucoma\x20and\x20reduces\x20IOP\x20by\x20<strong>decreasing\x20the\x20aqueous\x20production.</strong></p>\x0a<p><strong>Dorzolamide</strong>\x20is\x20a\x20Carbonic\x20anhydrase\x20inhibitor\x20used\x20in\x20glaucoma,\x20acting\x20by\x20<strong>reducing\x20aqueous\x20production.</strong></p>\x0a<p>&nbsp;</p>\x0a</div>\x0a</div>','BUEFG','warn','click','\x20>\x20','eFYFV','EUthW','Myotonic\x20Dystrophy','target','UrQyu','IJztg','131QYyyjN','ZbKOZ','correctCount','VJKPT','KcmLA','</span></div>','The\x20image\x20below\x20shows\x20the\x20Sites\x20of\x20action\x20of\x20various\x20antifungal\x20drugs.\x20Which\x20is\x20the\x20site\x20of\x20action\x20for\x20Rezafungin?','Pancreatic\x20Adenocarcinoma','ipkyF','Match\x20the\x20following\x20Seizure\x20types\x20in\x20Column\x20A\x20with\x20the\x20drugs\x20used\x20to\x20treat\x20them\x20in\x20Column\x20B.','tNRFX','Urothelial\x20carcinoma','\x22\x20data-src=\x22','classList','NFGpd','btPrM','Parkinson\x27s\x20Disease','eiiTu','Bookmark','IIXHj','nav-btn-incorrect','WugOx','2518884iIvJUE','DCKff','eFyOx','Orexin\x20Antagonist\x20used\x20for\x20Insomnia','NEET\x20PG\x20Mini\x20Test\x20Series','zgwQI','BqRaE','zcCJd','questionText','bookmarkedQuestions','MheSA','3205728BhKPDd','Orexin\x20Agonist\x20used\x20for\x20Narcolepsy','QLina','qxgIt','Daprodustat,\x20a\x20newly\x20approved\x20drug\x20is\x20used\x20in\x20the\x20treatment\x20of\x20which\x20of\x20the\x20following\x20conditions?','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','JRfUs','daSrB','cysyh','addEventListener','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Aspartoacylase\x20deficiency','removeItem','nkCeP','lNVce','BdsIT','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','Erenumab','fUkqb','CcGpR','selectedAnswer','oqEWO','BwKrV','EtWsc','Melatonin\x20Antagonist\x20used\x20for\x20Narcolepsy','rRujU','xTJUx','2|0|5|4|1|3','ABzpy','yTLlf','optionsContainer','nstqe','ywnhE','submitSection','totalTimeResult','nav-btn-correct','Which\x20of\x20the\x20following\x20is\x20true\x20for\x20Daridorexant?','toISOString','WncRL','forEach','wIqBE','markReviewText','yOQYG','AbMbo','LmgYq','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','split','modeModal','xDMWS','udSux','uzaFT','qloeN','fill','testModeReviewLegend','OsRru','quizFile','whqPa','vLBIX','nav-btn-bookmarked','YSvTy','VlZeu','strokeDashoffset','No\x20solution\x20available.','ojThJ','bHqIB','Mzwlm','closest','totalAttempted','Progress\x20loaded.','egmqt','ZaGGn','</span><span>','status','KAFdR','TBLZv','search','vonTY','getElementById','WPhrO','jDmCB','navBtn_','RaqRL','hVOdV','<p><strong>Tofersen\u00a0</strong>is\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>Amyotrophic\x20lateral\x20sclerosis\x20(ALS)</strong>.</p>\x0a<p><strong>Tofersen\x20</strong>is\x20an\x20<strong>antisense\x20oligonucleotide\x20</strong>indicated\x20for\x20treating\x20<strong>Amyotrophic\x20lateral\x20sclerosis\x20(ALS)\x20</strong>in\x20adults\x20with\u00a0a\x20mutation\x20in\x20the\x20<strong>superoxide\x20dismutase\x201\x20(SOD1)\x20gene.\x20</strong>It\x20acts\x20by<strong>\u00a0</strong>causing\x20<strong>degradation\x20of\x20SOD1\x20mRNA</strong>\x20after\x20binding\x20to\x20it,\x20which\x20results\x20in\x20a\x20<strong>reduction\x20of\x20SOD1\x20protein\x20synthesis.\u00a0</strong>The\x20most\x20common\x20adverse\x20effects\x20associated\x20with\x20the\x20use\x20of\x20Tofersen\x20are\x20<strong>pain,\x20fatigue</strong>,\x20arthralgia,\x20<strong>increased\x20WBC\x20count\x20in\x20CSF</strong>\x20and\x20myalgia.\u00a0</p>\x0a<p><strong>ALS</strong>\x20is\x20a\x20progressive\x20motor\x20neuron\x20disease.\x20It\x20presents\x20as\x20upper\x20motor\x20neuron\x20(<strong>UMN</strong>)\x20palsy\u00a0(exaggerated\x20reflexes,\x20extensor\x20plantar),\x20lower\x20motor\x20neuron\x20(<strong>LMN</strong>)\x20palsy\x20(muscle\x20weakness,\x20atrophy,\x20fasciculations),\x20and\u00a0<strong>pseudobulbar\x20palsy</strong>\x20(dysarthria,\x20tongue\x20spasticity),\x20with\x20normal\x20bladder,\x20bowel\x20and\x20sensory\x20functions.</p>\x0a<p>Other\x20options:\x20<strong>Parkinson\x27s\x20disease</strong>\x20is\x20a\x20neurodegenerative\x20disease\x20characterized\x20by\x20tremors\x20at\x20rest,\x20rigidity,\x20bradykinesia,\x20gait\x20dysfunction,\x20postural\x20instability,\x20speech\x20difficulty,\x20swallowing\x20impairment,\x20and\x20autonomic\x20disturbances.\x20<strong>Levodopa\x20and\x20carbidopa</strong>\x20combination\x20is\x20used\x20as\x20the\x20first\x20line\x20of\x20treatment.</p>\x0a<p><strong>Alzheimer\x27s\x20disease</strong>\x20is\x20the\u00a0most\x20common\u00a0cause\x20of\u00a0dementia\u00a0in\x20the\u00a0elderly.<strong>\x20</strong>Treatment\x20includes\x20drugs\x20like\x20<strong>Donepezil,\x20rivastigmine,\x20Galantamine\x20and\x20Memantine.</strong></p>\x0a<p><strong>Lewy\x20body\x20dementia\u00a0</strong>is\x20a\x20progressive\x20neurodegenerative\x20associated\x20with\u00a0dementia,\x20psychosis,\u00a0and\x20features\x20of\u00a0parkinsonism.\x20The\x20mainstay\x20of\x20treatment\x20is\x20symptomatic\x20management\x20which\x20includes\x20<strong>cholinesterase\x20inhibitors</strong>.</p>','0|1|2|5|3|4','CSGkD','mPfWY','EdmOM','SDcFf','Nivolumab\x20and\x20Relatlimab\x20combination\x20can\x20be\x20used\x20in\x20which\x20of\x20these\x20tumours?','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','pXtqK','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','width','VuxFX','hHAiH','JkovV','iqTzZ','<p>Features\x20of\x20<strong>frequent\x20falling</strong>,\x20<strong>staggering\x20gait,\x20depressed\x20deep\x20tendon\x20reflex</strong>\x20and\x20<strong>nystagmus</strong>,\x20and\x20the\x20<strong>expansion\x20of\x20GAA\x20trinucleotide\x20repeats</strong>\x20in\x20a\x2019-year-old\x20male\x20suggest<strong>\u00a0Friedrich\x27s\x20ataxia.\x20</strong><strong>Omaveloxolone</strong>\x20is\x20a\x20newly\x20FDA-approved\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>Friedrich’s\x20ataxia.</strong></p>\x0a<p><strong>Friedreich\x27s\x20ataxia\u00a0i</strong>s\x20the\x20most\x20common\x20form\x20of\u00a0<strong>inherited\x20</strong>ataxia.\x20It\x20is\x20an\x20<strong>autosomal\x20recessive</strong>\x20disorder\x20generally\x20occurring\x20in\x20individuals\x20less\x20than\x2025\x20years\x20of\x20age.\x20It\x20is\x20caused\x20by\x20the\x20expansion\x20of\x20a\x20<strong>GAA</strong>\u00a0<strong>trinucleotide\x20repeat\x20</strong>in\x20the\x20first\x20intron\x20of\x20a\x20gene\x20on\u00a0<strong>chromosome\x209q13</strong>\u00a0that\x20encodes\u00a0<strong>frataxin.\x20</strong>Patients\x20present\x20with<strong>\u00a0</strong>clinical\x20features\x20of\x20<strong>dysarthria,</strong>\u00a0progressive\u00a0<strong>staggering\x20gait</strong>,\x20frequent\x20falls,\x20<strong>nystagmus,</strong>\x20and\x20<strong>titubation</strong>(nodding\x20head\x20and\x20body\x20movements).</p>\x0a<p><strong>Omaveloxolone</strong>\x20was\x20recently\x20approved\x20by\x20the\x20FDA\x20for\x20treating\x20Friedrich’s\x20ataxia\x20in\x20adults\x20and\x20adolescents\x20aged\x2016\x20years\x20and\x20older.\x20Alanine\x20aminotransferase\x20(ALT),\x20aspartate\x20aminotransferase\x20(AST),\x20bilirubin,\x20B-type\x20natriuretic\x20peptide\x20(BNP),\x20and\x20lipid\x20profiles\x20should\x20be\x20documented\x20prior\x20to\x20initiating\x20the\x20<strong>oral\x20drug</strong>.</p>\x0a<p>The\x20exact\x20<strong>mechanism\x20of\x20action</strong>\x20of\x20the\x20drug\x20is\x20unknown,\x20but\x20it\x20has\x20been\x20shown\x20to\x20<strong>activate\x20the\x20Nuclear\x20factor\x20(erythroid-derived\x202)like\x202\x20(Nrf2)\x20pathway</strong>\x20in\x20vitro\x20and\x20in\x20vivo\x20in\x20animals\x20and\x20humans.\x20The\x20Nrf2\x20pathway\x20is\x20involved\x20in\x20the\x20<strong>cellular\x20response\x20to\x20oxidative\x20stress.\u00a0</strong></p>\x0a<p><strong>Adverse\x20effects</strong>\x20on\x20administration\x20are\x20<strong>elevation\x20of\x20liver\x20enzymes</strong>\x20(AST/ALT),\x20elevation\x20of\x20<strong>BNP</strong>(Brain\x20Natriuretic\x20Peptide),\x20headache,\x20nausea,\x20abdominal\x20pain,\x20fatigue,\x20diarrhea,\x20and\x20musculoskeletal\x20pain.\x20Omaveloxolone\x20is\x20<strong>metabolized\x20by\x20the\x20CYP3A4\x20cytochrome\x20enzyme</strong>\x20and\x20hence\x20can\x20interact\x20with\x20other\x20CYP3A4\x20substrates\x20like\x20Midazolam.\u00a0</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p><strong>Trofinetide</strong>(option\x20A)is\x20a\x20synthetic\x20<strong>analogue\x20of\x20IGF-1</strong>(Insulin-like\x20Growth\x20Factor-1)\x20recently\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>Rett\x20Syndrome</strong>.</p>\x0a<p><strong>Zavegepant</strong>(option\x20C)\x20is\x20a\x20calcitonin\x20gene-related\x20peptide\x20(<strong>CGRP</strong>)\u00a0<strong>antagonist\x20</strong>used\x20to\x20treat\x20<strong>acute\x20attacks\x20of</strong>\x20<strong>migraine.</strong></p>\x0a<p><strong>Erenumab</strong>(option\x20D)is\x20a\x20<strong>monoclonal\x20antibody</strong>\x20against\x20the\x20<strong>CGRP\x20receptor\x20</strong>used\x20in\x20the\x20<strong>prevention</strong>\x20of<strong>\x20migraine.</strong></p>\x0a<p>\u00a0</p>\x0a<p>\u00a0</p>\x0a<p>\u00a0</p>','replace','gJMiV','notAttempted','Previous\x20progress\x20cleared.','join','tfTpA','hMBsK','RCWfp','cvHmb','QQaLc','Rlhlx','PVJzU','completed','yXKfL','explanation_images','findIndex','incorrect','dHrtW','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','LFNbq','qqQoy','gray','Gastric\x20Adenocarcinoma','Hypoglycemia','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','dataset','border-gray-600','VKmUc','zGZGQ','Sytzh','application/vnd.apple.mpegurl','pop','fromCharCode','<p><strong>Rozanolixizumab</strong>\x20is\x20a\x20newly\x20FDA-approved\x20drug\x20indicated\x20for\x20use\x20in\x20patients\x20with\x20<strong>generalised\x20Myasthenia\x20gravis.</strong></p>\x0a<p><strong>Myasthenia\x20gravis</strong>\x20is\x20a\x20Neuromuscular-junction(NMJ)\x20disorder\x20due\x20to\x20<strong>autoimmune\x20</strong>damage\x20to\x20the\x20<strong>postsynaptic\x20acetylcholine\x20receptors\x20at\x20the\x20NMJ</strong>.\x20It\x20is\x20characterized\x20by\x20<strong>weakness</strong>&nbsp;and&nbsp;<strong>muscle\x20fatigue</strong>.\x20Weakness\x20increases\x20with\x20usage\x20and\x20muscle\x20movement\x20is\x20difficult\x20at\x20the\x20end\x20of\x20the\x20day.\x20It\x20affects\x20proximal<strong>\x20</strong>muscles\x20leading\x20to<strong>\x20weakness\x20of\x20the\x20limbs</strong>.\x20Ocular\x20features\x20like\x20<strong>ptosis</strong>&nbsp;and&nbsp;<strong>diplopia</strong>\x20can\x20also\x20be\x20seen.\x20<strong>Treatment\x20</strong>includes\x20<strong>Anticholinesterase</strong>\x20drugs\x20like\x20<strong>Pyridostigmine</strong>,\x20<strong>immunosuppression</strong>\x20and\x20even\x20<strong>Thymectomy</strong>\x20if\x20the\x20condition\x20is\x20associated\x20with\x20a\x20Thymoma.\x20Recently\x20<strong>Rozanolixizumab</strong>\x20has\x20been\x20approved\x20for\x20treating\x20cases\x20of\x20generalised\x20Myasthenia\x20gravis.</p>\x0a<p><strong>Rozanolixizumab</strong>\x20is\x20a\x20humanized\x20IgG4\x20<strong>monoclonal\x20antibody</strong>\x20that\x20binds\x20to\x20the<strong>&nbsp;Fc\x20receptor</strong>\x20(FcRn)\x20of\x20the\x20<strong>circulating\x20Autoantibodies\x20</strong>against\x20the\x20Acetyl-choline\x20receptors.\x20This\x20neutralisation\x20of\x20auto-antibodies\x20provides\x20clinical\x20relief\x20of\x20symptoms.\x20It\x20is\x20administered\x20through\x20a\x20<strong>subcutaneous</strong>\x20route.\x20The\x20most\x20common\x20<strong>adverse\x20reactions</strong>\x20noted\x20with\x20the\x20use\x20of\x20Rozanolixizumab\x20in\x20patients\x20with\x20generalised\x20Myasthenia\x20Gravis\x20are\x20<strong>headache,\x20infections,\x20</strong>diarrhoea<strong>,\x20</strong>fever<strong>,\x20hypersensitivity\x20reactions\x20</strong>and<strong>\x20</strong>nausea<strong>.</strong></p>\x0a<p><strong>Lambert-Eaton\x20myasthenic\x20syndrome&nbsp;(LEMS)</strong>\x20is\x20an\x20autoimmune\x20disorder\x20affecting\x20the&nbsp;<strong>presynaptic</strong>\x20membrane\x20at\x20the\x20NMJ.\x20Patients\x20present\x20with&nbsp;proximal\x20muscle\x20<strong>weakness&nbsp;of\x20the\x20lower\x20limbs</strong>,\x20<strong>ptosis</strong>,\x20and\x20<strong>diplopia</strong>.\x20However,\x20symptoms\x20might&nbsp;improve\x20after\x20brief\x20exercise.\x20<strong>Treatment</strong>\x20involves\x20<strong>plasmapheresis</strong>,\x20<strong>immunotherapy</strong>,\x20and\x20drugs\x20such\x20as\x20<strong>3,4-diaminopyridine\x20</strong>(3,4-DAP)\x20and\x20<strong>pyridostigmine</strong>.</p>\x0a<p><strong>Duchenne\x20muscular\x20dystrophy</strong>&nbsp;(DMD)\x20is\x20X-linked\x20muscular\x20dystrophy\x20due\x20to\x20mutations\x20in\x20the\x20dystrophin\x20gene.\x20It\x20most\x20commonly\x20affects&nbsp;boys&nbsp;in\x20their&nbsp;childhood.\x20Patients\x20initially\x20present\x20with&nbsp;<strong>proximal\x20muscle\x20weakness</strong>\x20predominantly\x20in\x20the\x20lower\x20limbs.&nbsp;<strong>Calf\x20muscle\x20hypertrophy</strong>\x20is\x20a\x20cardinal\x20feature.\x20Other\x20features\x20include\x20mental\x20retardation,\x20cardiac\x20failure,\x20and\x20myoglobinuria.\x20Treatment\x20includes\x20corticosteroids,\x20<strong>Eteplirsen</strong>&nbsp;and&nbsp;<strong>Casimersen.</strong>&nbsp;</p>\x0a<p><strong>Myotonic\x20dystrophy</strong>&nbsp;is\x20an&nbsp;autosomal\x20dominant&nbsp;disorder\x20affecting\x20multiple\x20systems.\x20It\x20is\x20associated\x20with&nbsp;<strong>skeletal\x20muscle\x20weakness,\x20cataracts,\x20endocrinopathy,\x20</strong>and<strong>&nbsp;cardiomyopathy</strong>.\x20The\x20<strong>treatment</strong>\x20is\x20mainly\x20<strong>symptomatic</strong>\x20however,\x20<strong>mexiletine</strong>\x20is\x20indicated\x20for\x20reducing\x20myotonia.</p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>','ThnvL','onclick','Duchenne\x20muscular\x20dystrophy','explanation_video','button','questionIndex','trace','nav-btn-current','14366XEOKzJ','timerContainer'];_0x5804=function(){return _0x365eb9;};return _0x5804();}const _0x3b866c=_0x877c;(function(_0x20991e,_0xfd4a4b){const _0x47c40a=_0x877c,_0x5243b7=_0x20991e();while(!![]){try{const _0x10bdcd=parseInt(_0x47c40a(0x1d0))/0x1*(-parseInt(_0x47c40a(0x27f))/0x2)+parseInt(_0x47c40a(0x1e6))/0x3+parseInt(_0x47c40a(0x1a4))/0x4*(-parseInt(_0x47c40a(0x2ff))/0x5)+parseInt(_0x47c40a(0x1f1))/0x6+parseInt(_0x47c40a(0x331))/0x7*(-parseInt(_0x47c40a(0x374))/0x8)+-parseInt(_0x47c40a(0x138))/0x9+-parseInt(_0x47c40a(0xd6))/0xa*(-parseInt(_0x47c40a(0x14f))/0xb);if(_0x10bdcd===_0xfd4a4b)break;else _0x5243b7['push'](_0x5243b7['shift']());}catch(_0x4b62a1){_0x5243b7['push'](_0x5243b7['shift']());}}}(_0x5804,0x8fd08));const _0x21426a=(function(){let _0x3bd9e7=!![];return function(_0x83d886,_0x12ef7d){const _0x2942a9=_0x3bd9e7?function(){const _0x1a2092=_0x877c;if(_0x12ef7d){const _0x384021=_0x12ef7d[_0x1a2092(0x16e)](_0x83d886,arguments);return _0x12ef7d=null,_0x384021;}}:function(){};return _0x3bd9e7=![],_0x2942a9;};}()),_0x152969=_0x21426a(this,function(){const _0xbd2cd3=_0x877c,_0x48fa77={'qqQoy':'(((.+)+)+)+$'};return _0x152969[_0xbd2cd3(0x12c)]()['search'](_0xbd2cd3(0xf7))[_0xbd2cd3(0x12c)]()[_0xbd2cd3(0x16a)](_0x152969)[_0xbd2cd3(0x23c)](_0x48fa77[_0xbd2cd3(0x269)]);});_0x152969();const _0x21816c=(function(){const _0x526476=_0x877c,_0x54bd3b={'tXqqB':function(_0xf0fdf3){return _0xf0fdf3();},'fTpMO':_0x526476(0x2a3),'CkALC':'modeModal','YfidG':function(_0x35e100,_0x213d3b){return _0x35e100===_0x213d3b;},'aTsQp':_0x526476(0xe6),'lXLjT':_0x526476(0x377)};let _0x2032e5=!![];return function(_0x171a26,_0x1e8d53){const _0x1f0403=_0x2032e5?function(){const _0x5c5a7b=_0x877c,_0xbf3c83={'vRqVq':function(_0x55a108){return _0x54bd3b['tXqqB'](_0x55a108);},'ekMDy':_0x54bd3b['fTpMO'],'hYFRm':function(_0x4915ef){return _0x4915ef();},'BqRaE':_0x54bd3b[_0x5c5a7b(0x2be)],'qXBJL':'flex'};if(_0x1e8d53){if(_0x54bd3b[_0x5c5a7b(0x11d)](_0x54bd3b[_0x5c5a7b(0x2e8)],_0x54bd3b[_0x5c5a7b(0x329)]))_0xbf3c83[_0x5c5a7b(0x388)](_0x5cdd70)?(_0x78433d[_0x5c5a7b(0x23e)]('modeModal')[_0x5c5a7b(0xf8)][_0x5c5a7b(0x1af)]=_0xbf3c83[_0x5c5a7b(0x1ae)],_0xbf3c83['hYFRm'](_0x350b62)):(_0x298177(),_0x494676['getElementById'](_0xbf3c83[_0x5c5a7b(0x1ec)])['style'][_0x5c5a7b(0x1af)]=_0xbf3c83['qXBJL']);else{const _0x1f01ea=_0x1e8d53[_0x5c5a7b(0x16e)](_0x171a26,arguments);return _0x1e8d53=null,_0x1f01ea;}}}:function(){};return _0x2032e5=![],_0x1f0403;};}()),_0xa4f757=_0x21816c(this,function(){const _0x5c777d=_0x877c,_0x1e7adf={'qNgbW':function(_0x2f6579){return _0x2f6579();},'ONkYH':function(_0x199b71,_0x2587f6){return _0x199b71(_0x2587f6);},'eiiTu':function(_0x2ba222,_0x1c3f2f){return _0x2ba222===_0x1c3f2f;},'gjESx':function(_0x53af13){return _0x53af13();},'ZrgUO':'abkZn','LFNbq':function(_0x4857ea,_0x49e1a3){return _0x4857ea+_0x49e1a3;},'oFtoy':'return\x20(function()\x20','ipkyF':_0x5c777d(0x371),'tqDQM':_0x5c777d(0x1c7),'NKGrN':'info','gUiWe':_0x5c777d(0x339),'xzvXj':_0x5c777d(0x2b4),'buguF':'table','ptQYd':_0x5c777d(0x27d),'VJKPT':function(_0x47332d,_0x55bf4f){return _0x47332d<_0x55bf4f;}};let _0x650cf9;try{if(_0x1e7adf['eiiTu'](_0x1e7adf[_0x5c777d(0x145)],_0x1e7adf[_0x5c777d(0x145)])){const _0x3a39c5=Function(_0x1e7adf[_0x5c777d(0x268)](_0x1e7adf['oFtoy'],_0x5c777d(0x28c))+');');_0x650cf9=_0x3a39c5();}else _0x5af7f3--,_0x1e7adf[_0x5c777d(0x102)](_0x38d4a8),_0x284504<=0x0&&(_0x1e7adf['ONkYH'](_0x51f9f1,_0x18b7d3),_0x1e7adf[_0x5c777d(0x1e1)](_0x5c44ad,_0x5c777d(0x1ac))?_0x1e7adf['gjESx'](_0x589c28):_0x1366f4());}catch(_0x4f84c6){_0x650cf9=window;}const _0x560ca2=_0x650cf9[_0x5c777d(0x285)]=_0x650cf9[_0x5c777d(0x285)]||{},_0x2fcbf1=[_0x1e7adf[_0x5c777d(0x1d8)],_0x1e7adf[_0x5c777d(0x28e)],_0x1e7adf[_0x5c777d(0x2ec)],_0x1e7adf[_0x5c777d(0x12d)],_0x1e7adf['xzvXj'],_0x1e7adf['buguF'],_0x1e7adf['ptQYd']];for(let _0x1cb013=0x0;_0x1e7adf[_0x5c777d(0x1d3)](_0x1cb013,_0x2fcbf1[_0x5c777d(0x1b5)]);_0x1cb013++){const _0x164cb8=_0x21816c[_0x5c777d(0x16a)][_0x5c777d(0x2c1)][_0x5c777d(0x358)](_0x21816c),_0x1d0654=_0x2fcbf1[_0x1cb013],_0x250096=_0x560ca2[_0x1d0654]||_0x164cb8;_0x164cb8[_0x5c777d(0x353)]=_0x21816c[_0x5c777d(0x358)](_0x21816c),_0x164cb8[_0x5c777d(0x12c)]=_0x250096[_0x5c777d(0x12c)][_0x5c777d(0x358)](_0x250096),_0x560ca2[_0x1d0654]=_0x164cb8;}});_0xa4f757();let questionsData=[{'text':_0x3b866c(0x24a),'choices':[{'id':0x1,'text':_0x3b866c(0x163)},{'id':0x2,'text':_0x3b866c(0x14a)},{'id':0x3,'text':'Non\x20small\x20cell\x20lung\x20cancer'},{'id':0x4,'text':_0x3b866c(0x1db)}],'correct_choice_id':0x1,'solution':'<p><strong>Nivolumab\x20and\x20Relatlimab\x20combination</strong>\x20can\x20be\x20used\x20in\x20patients\x20with\x20<strong>Malignant\x20Melanoma.</strong></p>\x0a<p>Both\x20<strong>Nivolumab</strong>\x20and\x20<strong>Relatlimab</strong>\x20are\x20<strong>Immune\x20checkpoint\x20inhibitors</strong>.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>A\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>combination\x20</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>of\x20<strong>N</strong></span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>ivolumab</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>,\x20a\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>PD-1\x20blocking\x20antibody</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>(programmed\x20death\x20receptor-1),\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>and\x20Relatlimab,\x20a\x20LAG-3\x20blocking\x20antibody\x20</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>(lymphocyte\x20activation\x20gene-3)\x20is\x20indicated\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>unresectable\x20or\x20metastatic\x20melanoma.</strong></p>\x0a<p>Binding\x20of\x20the<strong>\x20PD-1\x20ligands\x20</strong>(PD-L1\x20and\x20PD-L2)\x20to\x20the\x20PD-1\x20receptor\x20found\x20on\x20T\x20cells,\x20<strong>inhibits\x20T-cell\x20proliferation\x20and\x20cytokine\x20production.</strong>\x20Upregulation\x20of\x20PD-1\x20ligands\x20occurs\x20in\x20Malignant\x20melanoma\x20which\x20leads\x20to\x20inhibition\x20of\x20T-cell\x20immune\x20surveillance\x20of\x20tumours.\x20Similarly,\x20the<strong>\x20LAG-3\x20pathway\x20inhibits\x20T-cell\x20proliferation\x20and\x20cytokine\x20secretion.</strong>\x20The\x20<strong>drugs\x20which\x20inhibit\x20</strong>PD-1\x20or\x20LAG-3\x20and\x20other\x20similar\x20<strong>interactions\u00a0between\x20the\x20Tumour\x20and\x20Immune\x20cells</strong>\x20are\x20termed\x20<strong>Immune\x20checkpoint\x20inhibitors.</strong></p>\x0a<p>The\x20<strong>synergistic</strong>\x20<strong>combination</strong>\x20of\x20Nivolumab\x20(anti-PD-1)\x20and\x20Relatlimab\x20(anti-LAG-3)\x20results\x20in\x20<strong>increased\x20T-cell\x20activation</strong>\x20compared\x20to\x20the\x20activity\x20of\x20either\x20antibody\x20alone,\x20as\x20LAG-3\x20blockade\x20potentiates\x20the\x20anti-tumour\x20activity\x20of\x20PD-1\x20blockage,<strong>\x20inhibiting\x20tumour\x20growth\x20</strong>and\x20<strong>promoting\x20tumour\x20regression</strong>.</p>\x0a<p>The\x20drug\x20combination\x20is\x20given\x20by\x20<strong>intravenous</strong>\x20route\x20in\x20adults\x20as\x20well\x20as\x20children\x20more\x20than\x2012\x20years\x20of\x20age.\x20<strong>Adverse\x20effects</strong>\x20upon\x20usage\x20include\x20<strong>anaemia,\x20lymphocytopenia,\x20increased\x20AST,\x20increased\x20ALT,\x20</strong>and<strong>\x20Hyponatremia.</strong></p>\x0a<p>Many\x20other\x20immune\x20checkpoint\x20inhibitors\x20have\x20been\x20approved\x20for\x20the\x20treatment\x20of\x20various\x20tumours.\x20<strong>Pembrolizumab\x20</strong>which\x20acts\x20by\x20inhibiting\x20<strong>PD-1,\x20</strong>is\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>carcinoma\x20endometrium</strong>.</p>\x0a<p><strong>Atezolimumab</strong>\u00a0is\x20also\x20an\x20immune\x20checkpoint\x20inhibitor,\x20acts\x20by\x20inhibiting\x20<strong>PDL-1,</strong>\u00a0used\x20for\x20the\x20treatment\x20of\x20<strong>non-small\x20cell\x20lung\x20cancer</strong>.</p>\x0a<p><strong>Durvalumab</strong>\x20is\x20also\x20a\x20<strong>PD-L1\x20inhibitor</strong>\x20and\x20is\x20approved\x20for\x20use\x20in\x20<strong>metastatic\x20urothelial</strong>\u00a0<strong>cancer.</strong></p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x18d),'choices':[{'id':0x1,'text':'Recombinant\x20human\x20erythropoietin'},{'id':0x2,'text':'Recombinant\x20human\x20thrombopoietin'},{'id':0x3,'text':'Recombinant\x20human\x20granulocyte\x20colony-stimulating\x20factor'},{'id':0x4,'text':'Recombinant\x20human\x20granulocyte-macrophage\x20colony-stimulating\x20factor'}],'correct_choice_id':0x3,'solution':'<p><strong>Eflapegrastim\x20</strong>is\x20a\x20<strong>Recombinant\x20human\x20granulocyte\x20colony-stimulating\x20factor</strong>\x20(G-CSF).</p>\x0a<p>FDA\x20has\x20recently\x20approved\x20<strong>Eflapegrastim</strong>\x20to\x20<strong>decrease\x20the\x20incidence\x20of\x20infection</strong>,\x20in\x20adult\x20patients\x20receiving\x20myelosuppressive<strong>\x20</strong>anti<strong>-</strong>cancer<strong>\x20</strong>drugs<strong>.</strong>\x20<strong>Anti-cancer\x20drugs</strong>\x20can\x20frequently\x20cause\x20<strong>Myelosuppression</strong>,\x20which\x20manifests\x20as\x20febrile\x20neutropenia\x20and\x20increase\x20the\x20risk\x20of\x20recurrent\x20and\x20severe\x20infection\x20in\x20these\x20patients.\x20Thus,\x20<strong>recombinant\x20human\x20granulocyte\x20colony-stimulating\x20factor</strong>\x20(G-CSF)\x20class\x20of\x20drugs\x20are\x20given\x20to\x20correct\x20the\x20neutropenia.\x20Examples\x20of\x20G-CSF\x20are\x20<strong>eflapegrastim,\x20pegfilgrastim\x20and\x20filgrastim</strong>.&nbsp;</p>\x0a<p><strong>Eflapegrastim\x20</strong>binds\x20to\x20G-CSF\x20receptors\x20on\x20<strong>myeloid\x20progenitor\x20cells\x20and\x20neutrophils,</strong>\x20triggering\x20signalling\x20pathways\x20that\x20control\x20cell\x20differentiation,\x20proliferation,\x20migration\x20and\x20survival.\x20<strong>Adverse\x20effects\x20</strong>include\x20<strong>fatigue,</strong>\x20<strong>nausea,\x20diarrhoea,\x20bone\x20pain,\x20headache,\x20pyrexia,\x20anaemia,\x20rash,\x20myalgia,\x20arthralgia,\x20</strong>and<strong>\x20back\x20pain</strong>.&nbsp;</p>\x0a<p>Other\x20options:\x20<strong>Recombinant\x20human\x20erythropoietin\x20</strong>like\x20<strong>Epoetin\x20alfa</strong>&nbsp;and&nbsp;<strong>darbepoetin\x20alfa</strong>\x20are\x20used\x20in\x20the\x20treatment\x20of\x20<strong>anaemias</strong>\x20associated\x20with\x20surgery,\x20AIDS,\x20cancer\x20chemotherapy,\x20and\x20certain\x20chronic\x20inflammatory\x20conditions.\x20They\x20increase\x20erythropoiesis.</p>\x0a<p><strong>Recombinant\x20human\x20thrombopoietin\x20</strong>like\x20<strong>Oprelvekin</strong>\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>chemotherapy-induced\x20thrombocytopenia</strong>.\x20It\x20increases\x20thrombopoiesis.</p>\x0a<p><strong>Recombinant\x20human\x20granulocyte-macrophage\x20colony-stimulating\x20factor</strong>(GM-CSF)\x20like\x20<strong>Sargramostim</strong>\x20is\x20used\x20for\x20<strong>Myeloid\x20reconstitution\x20</strong>after\x20bone\x20marrow\x20transplant,\x20<strong>Prophylaxis\x20of\x20neutropenia\x20</strong>in\x20myelosuppressive\x20chemotherapy\x20and\x20<strong>Stem\x20cell\x20mobilization</strong>\x20in\x20donor\x20for\x20stem\x20cell\x20transplant.</p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x122),'choices':[{'id':0x1,'text':'Mafenide\x20acetate'},{'id':0x2,'text':_0x3b866c(0x31b)},{'id':0x3,'text':_0x3b866c(0x198)},{'id':0x4,'text':_0x3b866c(0x2a9)}],'correct_choice_id':0x3,'solution':'<p>The\x20above\x20image\x20shows\x20<strong>burns\x20with\x20eschar</strong>\x20and\x20among\x20the\x20above-mentioned\x20topical\x20applications,\x20<strong>Anacualase\x20</strong>is\x20used\x20to\x20<strong>remove\x20eschar.</strong></p>\x0a<p><strong>Eschar</strong>\x20is\x20a\x20form\x20of\x20<strong>tissue\x20reaction</strong>\x20that\x20can\x20form\x20in\x20patients\x20with\x20burns.\x20It\x20is\x20composed\x20of\x20<strong>dead\x20tissue\x20</strong>and\x20<strong>dried\x20secretions</strong>\x20from\x20a\x20skin\x20wound\x20following\x20a\x20burn\x20or\x20even\x20an\x20infectious\x20disease\x20of\x20the\x20skin.\x20An\x20eschar\x20prevents\x20topical\x20medications\x20to\x20reach\x20the\x20patient\x27s\x20viable\x20tissue\x20and\x20thus\x20hinders\x20the\x20healing\x20of\x20the\x20burn\x20wounds.</p>\x0a<p><strong>Anacualase</strong>\x20is\x20a\x20newly\x20approved\x20topical\x20agent\x20that<strong>\x20contains\x20proteolytic\x20enzymes\x20</strong>and\x20is\x20indicated\x20for\x20eschar\x20removal\x20in\x20adults\x20with\x20deep\x20partial\x20thickness\x20or\x20full-thickness\x20thermal\x20burn.\x20It\x20acts\x20by\x20<strong>dissolving\x20the\x20burn\x20wound\x20eschar\x20</strong>through\x20proteolytic\x20enzymes.\x20The\x20most\x20commonly\x20associated\x20adverse\x20reactions\x20are<strong>\x20pruritus</strong>\x20and<strong>\x20pyrexia.</strong>\x20<strong>Pain</strong>\x20during\x20application\x20can\x20be\x20managed\x20by\x20premedications\x20before\x20the\x20burn\x20dressing.</p>\x0a<p><strong>Mafenide\x20acetate</strong>\x20either\x20in\x20cream\x20or\x20solution\x20form\x20is\x20an\x20effective\x20<strong>topical\x20antimicrobial</strong>.\x20It\x20is\x20effective\x20even\x20in\x20the\x20presence\x20of\x20eschar\x20as\x20it\x20can&nbsp;<strong>penetrate\x20burn\x20eschar</strong>\x20to\x20reach\x20the\x20interface\x20with\x20the\x20patient\x27s\x20viable\x20tissue.\x20But\x20on\x20its\x20own\x20Mafenide\x20acetate\x20<strong>does\x20not\x20dissolve\x20and\x20remove\x20the\x20eschar.</strong></p>\x0a<p><strong>Silver\x20sulphadiazine\x20</strong>and\x20<strong>Silver\x20nitrate\x20</strong>are\x20both\x20topical\x20antimicrobial\x20agents\x20used\x20in\x20patients\x20with\x20burns\x20but\x20they\x20<strong>cannot\x20penetrate\x20eschar\x20</strong>and\x20thus\x20cannot\x20be\x20used\x20in\x20these\x20patients.</p>','explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/027d37b1ca6342988e84f01056058492.PNG'],'explanation_images':[]},{'text':_0x3b866c(0x1d6),'choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x4,'solution':_0x3b866c(0x1c4),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/2fb8d3f7b63c4fedaa872bc20a06ce64.PNG'],'explanation_images':[_0x3b866c(0xe3)]},{'text':_0x3b866c(0x29a),'choices':[{'id':0x1,'text':_0x3b866c(0x26b)},{'id':0x2,'text':_0x3b866c(0xd4)},{'id':0x3,'text':_0x3b866c(0x289)},{'id':0x4,'text':_0x3b866c(0x1d7)}],'correct_choice_id':0x2,'solution':'<p><strong>Futibatinib</strong>\x20is\x20a\x20newly\x20FDA-approved\x20drug\x20used\x20to\x20treat\x20<strong>locally\x20advanced\x20or\x20metastatic\x20intrahepatic\x20cholangiocarcinoma.</strong></p>\x0a<p><strong>Intrahepatic\x20Cholangiocarcinoma(ICC)\x20</strong>is\x20one\x20of\x20the\x20most\x20aggressive\x20tumours\x20which\x20originates\x20from\x20the\x20intrahepatic\x20bile\x20duct.\x20Histologically\x20ICCs\x20are\x20<strong>adenocarcinomas</strong>.\x20Only\x20a\x20minority\x20of\x20patients\x20present\x20with\x20a\x20resectable\x20disease.\x20Most\x20patients\x20present\x20when\x20the\x20disease\x20has\x20already\x20metastasized\x20to\x20the\x20liver,\x20stomach\x20or\x20colon.\u00a0</p>\x0a<p><strong>Futibatinib</strong>\x20is\x20a\x20<strong>kinase\x20inhibitor</strong>\x20indicated\x20for\x20the\x20treatment\x20of\x20adult\x20patients\x20with\x20previously\x20treated,\x20unresectable,\x20locally\x20advanced\x20or\x20metastatic\x20I<strong>ntrahepatic\x20cholangiocarcinoma</strong>\x20harbouring\x20<strong>fibroblast\x20growth\x20factor\x20receptor\x202\x20(FGFR2)\x20gene\x20fusions</strong>.\x20The\x20drug\x20is\x20also\x20active\x20in\x20patients\x20with\x20other\x20genetic\x20rearrangements/fusions\x20but\x20the\x20response\x20is\x20best\x20in\x20patients\x20with\x20FGFR\x20gene\x20fusions.</p>\x0a<p><strong>Mechanism\x20of\x20action:</strong>\x20Futibatinib\x20<strong>inhibits\x20FGFR\x20phosphorylation</strong>\x20and\x20downstream\x20signalling\x20and\x20<strong>decreases\x20cell\x20viability\x20in\x20cancer</strong>\x20cell\x20lines\x20with\x20FGFR\x20alterations.\x20It\x20is\x20<strong>metabolised\x20by</strong>\x20Cytochrome\x20enzyme<strong>-CYP3A</strong>.\x20Co-administration\x20of\x20CYP3A\x20inducers\x20and\x20inhibitors\x20should\x20therefore\x20be\x20avoided.\x20The\x20most\x20common\x20<strong>adverse\x20reactions</strong>\x20are\x20<strong>nail\x20toxicity,</strong>\x20<strong>musculoskeletal\x20pain</strong>,\x20constipation,\x20diarrhoea,\x20fatigue,\x20<strong>dry\x20mouth</strong>,\x20and\x20<strong>alopecia</strong>.</p>\x0a<p>Currently,\x20<strong>Futibatinib\x20is\x20not</strong>\x20approved\x20to\x20be\x20used\x20in\x20<strong>Gastric\x20Adenocarcinoma</strong>,\x20<strong>Hepatocellular\x20Carcinoma\x20</strong>and<strong>\x20Pancreatic\x20Adenocarcinoma.</strong></p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x133),'choices':[{'id':0x1,'text':_0x3b866c(0x1e0)},{'id':0x2,'text':'Alzheimer\x27s\x20Dementia'},{'id':0x3,'text':_0x3b866c(0x154)},{'id':0x4,'text':_0x3b866c(0x193)}],'correct_choice_id':0x4,'solution':_0x3b866c(0x244),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20delay\x20the\x20onset\x20of\x20Stage-3\x20in\x20patients\x20with\x20Stage-2\x20of\x20Type\x201\x20Diabetes?','choices':[{'id':0x1,'text':_0x3b866c(0x2e4)},{'id':0x2,'text':_0x3b866c(0x1a6)},{'id':0x3,'text':_0x3b866c(0x295)},{'id':0x4,'text':_0x3b866c(0x202)}],'correct_choice_id':0x2,'solution':'<p><strong>Teplizumab\x20</strong>is\x20a\x20recently\x20approved\x20drug\x20used\x20to\x20<strong>delay\x20the\x20onset\x20of\x20Stage-3</strong>\x20in\x20patients\x20with\x20Stage-2\x20of\x20<strong>Type\x201\x20Diabetes</strong>\x20Mellitus(Type\x201\x20DM).</p>\x0a<p><strong>Type\x201\x20DM</strong>\x20is\x20caused\x20due\x20to<strong>\x20immune-mediated\x20destruction</strong>\x20of\x20the\x20pancreatic\x20<strong>beta\x20cells</strong>\x20and\x20insulin\x20deficiency.\x20Patients\x20usually\x20present\x20in\x20adolescence\x20or\x20early\x20adulthood\x20with\x20classical\x20features\x20of\x20DM.\x20Based\x20on\x20further\x20evaluation,\x20patients\x20with\x20Type\x201\x20DM\x20can\x20be\x20further\x20categorised\x20into\x20three\x20stages.</p>\x0a<p><strong>Stage\x201\x20disease</strong>\x20is\x20characterized\x20by\x20the\x20development\x20of\x20<strong>two\x20or\x20more\x20islet\x20cell\x20autoantibodies</strong>\x20but\x20the\x20maintenance\x20of\x20<strong>normoglycemia</strong>.\x20<strong>Stage\x202\x20disease\x20i</strong>s\x20defined\x20by\x20continued\x20autoimmunity\x20and\x20the\x20<strong>development\x20of\x20dysglycemia</strong>(due\x20to\x20progressive\x20Beta\x20cell\x20destruction).\x20<strong>Stage\x203</strong>\x20is\x20defined\x20by\x20the\x20development\x20of\x20<strong>hyperglycemia</strong>\x20that\x20exceeds\x20the\x20diagnostic\x20criteria\x20for\x20the\x20diagnosis\x20of\x20diabetes.</p>\x0a<p><strong>Teplizumab\x20</strong>is\x20a\x20new\x20drug\x20which\x20can\x20delay\x20the\x20onset\x20of\x20Stage-3\x20of\x20Type\x201\x20DM\x20in\x20patients\x20with\x20Stage-2\x20of\x20Type\x201\x20DM.\x20It\x20acts\x20by\x20<strong>binding\x20to\x20CD-3\x20of\x20T\x20cells</strong>\x20and\x20possibly\x20does\x20<strong>partial\x20agonistic\x20signalling\x20</strong>and\x20<strong>deactivation\x20of\x20pancreatic\x20beta\x20cell\x20autoreactive\x20T\x20lymphocytes.</strong>\x20Thus\x20the\x20progressive\x20destruction\x20of\x20Beta\x20cells\x20in\x20the\x20pancreas\x20is\x20delayed.\x20The\x20adverse\x20effects\x20of\x20the\x20drug\x20include\x20l<strong>ymphopenia</strong>\x20and\x20<strong>severe\x20infections</strong>,\x20<strong>rash</strong>,\x20<strong>hypersensitivity</strong>\x20reactions\x20and\x20<strong>headache</strong>.</p>\x0a<p>&nbsp;</p>\x0a<p>Other\x20options:\x20<strong>Omaveloxolone</strong>\x20is\x20an\x20<strong>activato</strong>r\x20of\x20<strong>Nrf2</strong>,\x20a\x20newly\x20FDA-approved\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>Friedrich&rsquo;s\x20ataxia.</strong></p>\x0a<p><strong>\x20Insulin</strong>\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20in\x20patients\x20with\x20<strong>Type\x201\x20DM</strong>,\x20but\x20it\x20does\x20not\x20affect\x20the\x20disease\x20progression.</p>\x0a<p><strong>Erenumab\x20</strong>is\x20a\x20<strong>CGRPreceptor\x20antagonist&nbsp;</strong>used\x20in\x20the\x20treatment\x20of\x20an<strong>\x20acute\x20attack\x20of\x20migraine</strong></p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x1d9),'choices':[{'id':0x1,'text':'A-2,\x20B-1,\x20C-4,\x20D-3'},{'id':0x2,'text':'A-2,B-1,\x20C-3,\x20D-4'},{'id':0x3,'text':'A-1,\x20B-2,\x20C-3,\x20D-4'},{'id':0x4,'text':_0x3b866c(0x34f)}],'correct_choice_id':0x2,'solution':'<p>The\x20correct\x20match\x20is:</p>\x0a<table\x20style=\x22height:\x20208.945px;\x20width:\x20434px;\x22\x20width=\x22415\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2045.375px;\x22>\x0a<td\x20style=\x22width:\x20251.477px;\x20height:\x2045.375px;\x22>A.\x20West\x20Syndrome</td>\x0a<td\x20style=\x22width:\x20153.93px;\x20height:\x2045.375px;\x22>2.\x20ACTH</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2078.7969px;\x22>\x0a<td\x20style=\x22width:\x20251.477px;\x20text-align:\x20left;\x20height:\x2078.7969px;\x22>B.\x20cyclin-dependent\x20kinase-like\x205\x20(CDKL5)\x20deficiency\x20disorder</td>\x0a<td\x20style=\x22width:\x20153.93px;\x20height:\x2078.7969px;\x22>1.\x20Ganaxolone</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2043.3828px;\x22>\x0a<td\x20style=\x22width:\x20251.477px;\x20height:\x2043.3828px;\x22>C.\x20Lennox\x20Gestaut\x20Syndrome</td>\x0a<td\x20style=\x22width:\x20153.93px;\x20height:\x2043.3828px;\x22>3.\x20Sodium\x20Valproate</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2041.3906px;\x22>\x0a<td\x20style=\x22width:\x20251.477px;\x20height:\x2041.3906px;\x22>D.\x20Typical\x20Absence\x20Seizure</td>\x0a<td\x20style=\x22width:\x20153.93px;\x20height:\x2041.3906px;\x22>4.\x20Ethosuximide</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>&nbsp;</p>\x0a<p><strong>West\x20Syndrome</strong>&nbsp;is\x20a\x20rare\x20type\x20of\x20epilepsy\x20syndrome\x20that\x20begins\x20in&nbsp;<strong>infancy</strong>.\x20It\x20is\x20characterized\x20by\x20a\x20triad\x20of\x20<strong>Infantile\x20spasms</strong>,<strong>&nbsp;developmental\x20regression</strong>,\x20and<strong>&nbsp;hypsarrhythmia</strong>\x20(on\x20EEG).\x20The\x20drug\x20of\x20choice\x20for\x20West\x20syndrome\x20is&nbsp;<strong>ACTH</strong>(Adreno\x20Corticotrophic\x20Hormone)\x20injections.\x20The\x20drug\x20of\x20choice\x20for\x20infantile\x20spasms<strong>&nbsp;</strong>associated\x20with\x20<strong>tuberous</strong>\x20<strong>sclerosis</strong>\x20is&nbsp;<strong>vigabatrin</strong>.</p>\x0a<p><strong>Cyclin-dependent\x20kinase-like\x205\x20(CDKL5)\x20deficiency</strong>\x20causes\x20<strong>developmental\x20encephalopathy</strong>\x20which\x20presents\x20with\x20<strong>epilepsy,\x20hypotonia,\x20developmental\x20disabilities\x20</strong>and<strong>\x20cortical\x20visual\x20impairment</strong>.\x20<strong>Ganaxolone</strong>\x20is\x20a\x20recently\x20approved\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>seizures</strong>\x20associated\x20with\x20CDKL5\x20deficiency.</p>\x0a<p>The\x20exact\x20<strong>mechanism\x20of\x20action</strong>\x20of\x20Ganaxolone\x20is\x20unknown,\x20but\x20its\x20<strong>anticonvulsant\x20effects</strong>\x20are\x20thought\x20to\x20result\x20from\x20<strong>positive\x20allosteric\x20modulation\x20of\x20the\x20GABA-A\x20receptor</strong>\x20in\x20the\x20CNS.\x20It\x20can\x20be\x20used\x20in\x20adults\x20as\x20well\x20as\x20children\x20older\x20than\x202\x20years\x20of\x20age.\x20The\x20most\x20common\x20<strong>adverse\x20reactions\x20</strong>associated\x20with\x20the\x20drug\x20are<strong>\x20somnolence,\x20pyrexia,\x20salivary\x20hypersecretion\x20</strong>and<strong>\x20seasonal\x20allergy.</strong>&nbsp;</p>\x0a<p><strong>Lennox-Gastaut\x20syndrome\x20usually</strong>&nbsp;starts\x20between\x20the\x20age\x20of\x202\x20and\x2010\x20years.\x20It\x20consists\x20of\x20a&nbsp;<strong>triad</strong>\x20of\x20<strong>Developmental\x20delay</strong>,\x20<strong>Multiple\x20seizure\x20types\x20</strong>(including\x20atypical\x20absences,\x20myoclonic,\x20astatic,\x20and\x20tonic\x20seizures)\x20and\x20<strong>characteristic\x20EEG\x20findings</strong>\x20(<strong>1&ndash;2\x20Hz\x20spike&nbsp;and\x20slow\x20waves</strong>).\x20The\x20<strong>drug\x20of\x20choice\x20f</strong>or\x20Lennox-Gastaut\x20Syndrome\x20is\x20<strong>Sodium\x20Valproate</strong>.\x20Other\x20drugs\x20used\x20for\x20treatment\x20include\x20lamotrigine,\x20topiramate\x20and\x20clobazam.&nbsp;</p>\x0a<p><strong>Typical\x20absence\x20Seizures</strong>\x20are\x20characterized\x20by&nbsp;sudden,&nbsp;<strong>brief\x20lapses\x20of\x20consciousness</strong>&nbsp;with&nbsp;<strong>preserved\x20postural\x20control</strong>&nbsp;and&nbsp;<strong>no\x20post-ictal\x20confusion.&nbsp;</strong>Usually,\x20the\x20seizure\x20occurs\x20in\x20children\x20aged\x20four\x20to\x20ten\x20years\x20and\x20<strong>lasts\x20only\x20a\x20few\x20seconds.</strong>\x20<strong>Ethosuximide</strong>&nbsp;and&nbsp;<strong>sodium\x20valproate</strong>&nbsp;are\x20used\x20as\x20first-line\x20therapy\x20for&nbsp;<strong>absence\x20seizures.</strong></p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x215),'choices':[{'id':0x1,'text':'Melatonin\x20Analogue\x20used\x20for\x20insomnia'},{'id':0x2,'text':_0x3b866c(0x209)},{'id':0x3,'text':_0x3b866c(0x1e9)},{'id':0x4,'text':_0x3b866c(0x1f2)}],'correct_choice_id':0x3,'solution':_0x3b866c(0x2f5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20the\x20most\x20common\x20adverse\x20effect\x20associated\x20with\x20Bexagliflozin?','choices':[{'id':0x1,'text':_0x3b866c(0x32f)},{'id':0x2,'text':_0x3b866c(0x346)},{'id':0x3,'text':_0x3b866c(0x137)},{'id':0x4,'text':_0x3b866c(0x26c)}],'correct_choice_id':0x2,'solution':_0x3b866c(0xf6),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x33f),'choices':[{'id':0x1,'text':_0x3b866c(0x376)},{'id':0x2,'text':_0x3b866c(0x2e4)},{'id':0x3,'text':_0x3b866c(0xd9)},{'id':0x4,'text':_0x3b866c(0x202)}],'correct_choice_id':0x2,'solution':_0x3b866c(0x254),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x1f5),'choices':[{'id':0x1,'text':'Open\x20Angle\x20Glaucoma'},{'id':0x2,'text':_0x3b866c(0x2b7)},{'id':0x3,'text':'Post\x20partum\x20Hemorrhage'},{'id':0x4,'text':_0x3b866c(0x34e)}],'correct_choice_id':0x2,'solution':_0x3b866c(0x16d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Rozanolixizumab\x20is\x20indicated\x20for\x20the\x20treatment\x20of\x20which\x20of\x20the\x20following\x20conditions?','choices':[{'id':0x1,'text':'Myasthenia\x20gravis'},{'id':0x2,'text':_0x3b866c(0x107)},{'id':0x3,'text':_0x3b866c(0x279)},{'id':0x4,'text':_0x3b866c(0x1cc)}],'correct_choice_id':0x1,'solution':_0x3b866c(0x276),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0xf3),'choices':[{'id':0x1,'text':'Tay-Sachs\x20disease'},{'id':0x2,'text':_0x3b866c(0x12a)},{'id':0x3,'text':'Gaucher\x20Disease'},{'id':0x4,'text':_0x3b866c(0x125)}],'correct_choice_id':0x2,'solution':_0x3b866c(0x2bb),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x36a),'choices':[{'id':0x1,'text':_0x3b866c(0x367)},{'id':0x2,'text':'Paroxysmal\x20cold\x20hemoglobinuria'},{'id':0x3,'text':_0x3b866c(0x313)},{'id':0x4,'text':_0x3b866c(0x153)}],'correct_choice_id':0x4,'solution':_0x3b866c(0x11f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x11e),'choices':[{'id':0x1,'text':_0x3b866c(0x2d6)},{'id':0x2,'text':_0x3b866c(0x324)},{'id':0x3,'text':_0x3b866c(0x2e1)},{'id':0x4,'text':_0x3b866c(0xdd)}],'correct_choice_id':0x2,'solution':_0x3b866c(0x286),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x191),'choices':[{'id':0x1,'text':_0x3b866c(0x299)},{'id':0x2,'text':_0x3b866c(0x37b)},{'id':0x3,'text':'5\x27\x20Nucleotidase\x20deficiency'},{'id':0x4,'text':_0x3b866c(0x1fc)}],'correct_choice_id':0x2,'solution':_0x3b866c(0x2aa),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x126),'choices':[{'id':0x1,'text':_0x3b866c(0x370)},{'id':0x2,'text':_0x3b866c(0x301)},{'id':0x3,'text':_0x3b866c(0x365)},{'id':0x4,'text':_0x3b866c(0x336)}],'correct_choice_id':0x4,'solution':_0x3b866c(0x1c5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3b866c(0x321),'choices':[{'id':0x1,'text':_0x3b866c(0x2a5)},{'id':0x2,'text':'As\x20a\x20disinfectant\x20in\x20labs'},{'id':0x3,'text':'As\x20a\x20chemotherapy\x20agent'},{'id':0x4,'text':_0x3b866c(0x117)}],'correct_choice_id':0x4,'solution':_0x3b866c(0xe1),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20is\x20approved\x20for\x20prophylaxis\x20against\x20respiratory\x20syncytial\x20virus\x20(RSV)\x20infection?','choices':[{'id':0x1,'text':'Ribavirin'},{'id':0x2,'text':_0x3b866c(0x1c0)},{'id':0x3,'text':_0x3b866c(0x31d)},{'id':0x4,'text':'Oseltamivir'}],'correct_choice_id':0x3,'solution':_0x3b866c(0x135),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/06fa65cfa6304e6e8d0d2f9867d1bbadx1280x960.JPEG']}],quizName=_0x3b866c(0xed);function _0x877c(_0x7fe219,_0xfe6fb7){const _0x29291d=_0x5804();return _0x877c=function(_0xa4f757,_0x21816c){_0xa4f757=_0xa4f757-0xd1;let _0x2077e2=_0x29291d[_0xa4f757];return _0x2077e2;},_0x877c(_0x7fe219,_0xfe6fb7);}const quizFilename=_0x3b866c(0x103);let hierarchy=[_0x3b866c(0x34c),_0x3b866c(0x1ea),_0x3b866c(0x30e)];if(window['location'][_0x3b866c(0x2c7)][_0x3b866c(0xdc)](_0x3b866c(0x190))){const customData=JSON[_0x3b866c(0x31e)](localStorage[_0x3b866c(0x124)]('customQuizData'));if(customData){const WaISaZ=_0x3b866c(0x245)[_0x3b866c(0x21f)]('|');let AtMbAP=0x0;while(!![]){switch(WaISaZ[AtMbAP++]){case'0':questionsData=customData[_0x3b866c(0x2d0)];continue;case'1':quizName=customData['name'];continue;case'2':hierarchy=customData[_0x3b866c(0xec)];continue;case'3':document[_0x3b866c(0x23e)](_0x3b866c(0x29e))[_0x3b866c(0x343)]=questionsData['length'];continue;case'4':document[_0x3b866c(0x23e)](_0x3b866c(0x19a))[_0x3b866c(0x343)]=hierarchy[_0x3b866c(0x259)](_0x3b866c(0x1c9));continue;case'5':document[_0x3b866c(0x326)]=quizName+_0x3b866c(0x195);continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x3b866c(0x100),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date[_0x3b866c(0x2cd)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x3b866c(0x1b5)])[_0x3b866c(0x225)](null)[_0x3b866c(0x32e)](()=>({'status':_0x3b866c(0x188),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x3b866c(0x1b5)]};function saveProgress(){const _0x45e69f=_0x3b866c,_0x5637e8={'tfTpA':'userHistory'};if(isQuizCompleted)return;const _0x4e83ec=JSON[_0x45e69f(0x31e)](localStorage[_0x45e69f(0x124)](_0x5637e8['tfTpA']))||{};_0x4e83ec[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x45e69f(0x171),'lastSeen':new Date()['toISOString']()},localStorage[_0x45e69f(0x303)](_0x5637e8[_0x45e69f(0x25a)],JSON[_0x45e69f(0x17b)](_0x4e83ec));}function loadProgress(){const _0x5d9446=_0x3b866c,_0x42e0cd={'qrecv':function(_0x1b4c1f){return _0x1b4c1f();},'CLlLd':_0x5d9446(0x2f0),'ZBbEs':function(_0x53f3eb,_0x40926b){return _0x53f3eb===_0x40926b;},'TvBVm':_0x5d9446(0x114),'ilweM':'wsRRh','MnmTE':_0x5d9446(0x235)},_0x387103=JSON[_0x5d9446(0x31e)](localStorage[_0x5d9446(0x124)]('userHistory'))||{},_0x3028a7=_0x387103[quizFilename];if(_0x3028a7){if(_0x42e0cd['ZBbEs'](_0x42e0cd['TvBVm'],_0x42e0cd[_0x5d9446(0x36c)]))_0x42e0cd[_0x5d9446(0x33e)](_0x4155f2),_0x5a116e['getElementById'](_0x5d9446(0x220))['style'][_0x5d9446(0x1af)]=_0x42e0cd[_0x5d9446(0x106)];else{const _0x1419f1=_0x5d9446(0x20c)[_0x5d9446(0x21f)]('|');let _0x8b177a=0x0;while(!![]){switch(_0x1419f1[_0x8b177a++]){case'0':stats=_0x3028a7['stats'];continue;case'1':console[_0x5d9446(0x371)](_0x42e0cd[_0x5d9446(0x2ae)]);continue;case'2':questionStates=_0x3028a7['questionStates'];continue;case'3':return!![];case'4':currentMode=_0x3028a7[_0x5d9446(0x1aa)];continue;case'5':currentQuestionIndex=_0x3028a7[_0x5d9446(0x199)];continue;}break;}}}return![];}function clearProgress(){const _0x4d19e6=_0x3b866c,_0x28c748={'ABzpy':_0x4d19e6(0x296),'ttVll':_0x4d19e6(0x258)},_0x2f626=JSON[_0x4d19e6(0x31e)](localStorage['getItem'](_0x28c748[_0x4d19e6(0x20d)]))||{};_0x2f626[quizFilename]&&(delete _0x2f626[quizFilename],localStorage[_0x4d19e6(0x303)](_0x4d19e6(0x296),JSON[_0x4d19e6(0x17b)](_0x2f626)),console['log'](_0x28c748[_0x4d19e6(0x2bd)]));}function markQuizAsCompleted(){const _0xa2ef9a=_0x3b866c,_0x5e6798={'AWAdx':'userHistory','XWREk':_0xa2ef9a(0x261)},_0xd23ffd=JSON[_0xa2ef9a(0x31e)](localStorage[_0xa2ef9a(0x124)](_0x5e6798['AWAdx']))||{},_0x34b32e=questionsData[_0xa2ef9a(0x1b5)],_0x4cc773=stats['correctAnswers']||0x0;_0xd23ffd[quizFilename]={'score':_0x4cc773,'total':_0x34b32e,'status':_0x5e6798[_0xa2ef9a(0x16b)],'completedOn':new Date()[_0xa2ef9a(0x216)]()},localStorage[_0xa2ef9a(0x303)](_0x5e6798[_0xa2ef9a(0x2ad)],JSON['stringify'](_0xd23ffd));}const urlParams=new URLSearchParams(window[_0x3b866c(0x1bd)][_0x3b866c(0x23c)]),startAt=parseInt(urlParams[_0x3b866c(0x14b)](_0x3b866c(0x12f))),resume=urlParams[_0x3b866c(0x14b)](_0x3b866c(0x379))==='true';function goBack(){const _0x231f94=_0x3b866c,_0x461f63={'ZJnpW':function(_0x467be6){return _0x467be6();}};if(!isQuizCompleted)_0x461f63[_0x231f94(0x2e7)](saveProgress);window['location'][_0x231f94(0xeb)]=document[_0x231f94(0x149)]||'index.html';}function selectMode(_0x46abea){const _0x44862c=_0x3b866c,_0x5342fb={'cMWBZ':_0x44862c(0x220),'kFKfP':function(_0x344426){return _0x344426();}};currentMode=_0x46abea,document[_0x44862c(0x23e)](_0x5342fb[_0x44862c(0x2f2)])[_0x44862c(0xf8)][_0x44862c(0x1af)]=_0x44862c(0x2a3),_0x5342fb[_0x44862c(0x287)](initializeQuiz);}function initializeQuiz(){const _0x5c6540=_0x3b866c,_0x4de8f1={'tNRFX':_0x5c6540(0x1bc),'twwGk':_0x5c6540(0x226),'CSGkD':_0x5c6540(0x35d),'ThnvL':function(_0x554306,_0x59efcd){return _0x554306===_0x59efcd;},'iMmNm':_0x5c6540(0x13b),'LjKfw':_0x5c6540(0x2a3),'UBmcg':_0x5c6540(0x1b4),'zCvOx':'studyModeLegend','fDxfi':'testModeLegend','IhKiz':_0x5c6540(0x212),'rgSEC':_0x5c6540(0x2f0),'ecgFE':function(_0x361eee,_0x59471e){return _0x361eee===_0x59471e;},'mrteU':'timed_study','pwlTP':'timed_exam','ZHBsX':'timerContainer','nFCQy':_0x5c6540(0x328),'NyTeo':function(_0xdda61,_0x460011){return _0xdda61(_0x460011);},'AzpUg':function(_0x7b1663,_0x7aa597){return _0x7b1663>=_0x7aa597;},'YByfg':function(_0x47516f,_0x38372f){return _0x47516f<_0x38372f;},'EpGUv':function(_0x1a1f52){return _0x1a1f52();}};quizStartTime=Date[_0x5c6540(0x2cd)]();const _0xf35f7e=document[_0x5c6540(0x23e)](_0x4de8f1[_0x5c6540(0x1da)]),_0x3d08ef=document['getElementById'](_0x5c6540(0xf0)),_0x4d6ee7=document['getElementById'](_0x4de8f1[_0x5c6540(0x2e2)]),_0x2cf19f=currentMode===_0x4de8f1[_0x5c6540(0x246)]||_0x4de8f1[_0x5c6540(0x277)](currentMode,_0x5c6540(0x1ac));document[_0x5c6540(0x23e)](_0x4de8f1['iMmNm'])[_0x5c6540(0xf8)][_0x5c6540(0x1af)]=_0x2cf19f?_0x4de8f1[_0x5c6540(0x151)]:_0x4de8f1[_0x5c6540(0x2c8)],document[_0x5c6540(0x23e)](_0x4de8f1[_0x5c6540(0x2ed)])[_0x5c6540(0xf8)]['display']=_0x2cf19f?'none':_0x5c6540(0x1b4),document[_0x5c6540(0x23e)](_0x4de8f1[_0x5c6540(0x10b)])[_0x5c6540(0xf8)][_0x5c6540(0x1af)]=_0x2cf19f?_0x4de8f1[_0x5c6540(0x2c8)]:_0x4de8f1[_0x5c6540(0x151)],document[_0x5c6540(0x23e)](_0x4de8f1['IhKiz'])[_0x5c6540(0xf8)][_0x5c6540(0x1af)]=_0x2cf19f?_0x4de8f1[_0x5c6540(0x2c8)]:_0x4de8f1[_0x5c6540(0x151)],_0xf35f7e['style'][_0x5c6540(0x1af)]=_0x2cf19f?_0x4de8f1[_0x5c6540(0x151)]:_0x4de8f1[_0x5c6540(0x156)],_0x3d08ef[_0x5c6540(0xf8)]['display']=_0x2cf19f?_0x5c6540(0x2f0):_0x4de8f1['LjKfw'],_0x4d6ee7[_0x5c6540(0xf8)][_0x5c6540(0x1af)]=_0x2cf19f?_0x4de8f1[_0x5c6540(0x156)]:_0x4de8f1['LjKfw'],(_0x4de8f1[_0x5c6540(0x2f1)](currentMode,_0x4de8f1[_0x5c6540(0x132)])||_0x4de8f1[_0x5c6540(0x277)](currentMode,_0x4de8f1['pwlTP']))&&document[_0x5c6540(0x23e)](_0x4de8f1['ZHBsX'])['classList']['remove'](_0x4de8f1[_0x5c6540(0x1b6)]),!_0x4de8f1[_0x5c6540(0x342)](isNaN,startAt)&&_0x4de8f1[_0x5c6540(0x322)](startAt,0x0)&&_0x4de8f1['YByfg'](startAt,questionsData[_0x5c6540(0x1b5)])&&(currentQuestionIndex=startAt),_0x4de8f1[_0x5c6540(0x35c)](loadBookmarkedQuestions),_0x4de8f1[_0x5c6540(0x35c)](generateQuestionNav),updateStats(),displayQuestion();}function generateQuestionNav(){const _0x525c72=_0x3b866c,_0x2e4b56={'vScmp':function(_0x9a510e,_0x439048){return _0x9a510e<_0x439048;},'mTJtN':_0x525c72(0x27b),'YEqRq':function(_0x3ecc83,_0xb29bf4){return _0x3ecc83+_0xb29bf4;},'fUkqb':_0x525c72(0x354),'IUICn':function(_0x28d892){return _0x28d892();}},_0x5ed1e7=document['getElementById'](_0x525c72(0x2fb));_0x5ed1e7['innerHTML']='';for(let _0x5119e7=0x0;_0x2e4b56[_0x525c72(0x112)](_0x5119e7,questionsData['length']);_0x5119e7++){const _0x30acb1=document['createElement'](_0x2e4b56[_0x525c72(0x12b)]);_0x30acb1['textContent']=_0x2e4b56[_0x525c72(0xf4)](_0x5119e7,0x1),_0x30acb1[_0x525c72(0x300)]=_0x2e4b56[_0x525c72(0x203)],_0x30acb1[_0x525c72(0x278)]=()=>jumpToQuestion(_0x5119e7),_0x30acb1['id']=_0x525c72(0x241)+_0x5119e7,_0x5ed1e7[_0x525c72(0x2a7)](_0x30acb1);}_0x2e4b56['IUICn'](updateQuestionNav);}function updateQuestionNav(){const _0x56e7f9=_0x3b866c,_0x8af6b2={'aBUcN':_0x56e7f9(0x220),'wrZsU':_0x56e7f9(0x2a3),'vOZTa':function(_0x41d1ec){return _0x41d1ec();},'gJMiV':function(_0x1dca8a){return _0x1dca8a();},'hMBsK':function(_0x53f13a){return _0x53f13a();},'RCWfp':function(_0x2e3c66,_0x390819){return _0x2e3c66<_0x390819;},'kZhxg':function(_0x335c1a,_0x135ac5){return _0x335c1a===_0x135ac5;},'SorVK':function(_0x2b5d61,_0x563198){return _0x2b5d61===_0x563198;},'XhbGT':_0x56e7f9(0x1f8),'JkovV':_0x56e7f9(0x2b3),'HcHtF':_0x56e7f9(0x22b),'QZJHq':_0x56e7f9(0x104),'pFsXT':_0x56e7f9(0x100),'rtLpg':_0x56e7f9(0x2af),'QeLIA':_0x56e7f9(0x315),'YkBeL':_0x56e7f9(0x349),'BLhIh':function(_0x4c3299,_0x44cce2){return _0x4c3299===_0x44cce2;},'raSfI':_0x56e7f9(0x265),'BFCwm':_0x56e7f9(0x1e4),'dstbY':function(_0x13b047,_0x260e66){return _0x13b047!==_0x260e66;},'UKjTH':'nav-btn-answered'};for(let _0x35ed39=0x0;_0x8af6b2[_0x56e7f9(0x25c)](_0x35ed39,questionsData[_0x56e7f9(0x1b5)]);_0x35ed39++){const _0x4be9a9=document[_0x56e7f9(0x23e)](_0x56e7f9(0x241)+_0x35ed39),_0x3aff10=questionStates[_0x35ed39];let _0x58f66d='';if(_0x8af6b2[_0x56e7f9(0x316)](_0x35ed39,currentQuestionIndex))_0x8af6b2[_0x56e7f9(0x187)](_0x8af6b2[_0x56e7f9(0x115)],_0x8af6b2[_0x56e7f9(0x252)])?(_0x5bf33d=_0x28be37,_0x51933a[_0x56e7f9(0x23e)](_0x8af6b2[_0x56e7f9(0x35f)])[_0x56e7f9(0xf8)][_0x56e7f9(0x1af)]=_0x8af6b2[_0x56e7f9(0xee)],_0x8af6b2[_0x56e7f9(0x373)](_0x5a23b1)):_0x58f66d=_0x56e7f9(0x27e);else{if(_0x3aff10[_0x56e7f9(0x320)])_0x58f66d=_0x8af6b2[_0x56e7f9(0x2dd)];else{if(_0x3aff10[_0x56e7f9(0x29c)])_0x58f66d=_0x8af6b2['QZJHq'];else{if(_0x8af6b2[_0x56e7f9(0x187)](currentMode,_0x8af6b2[_0x56e7f9(0x35e)])||currentMode===_0x8af6b2[_0x56e7f9(0x1b8)]){if(_0x56e7f9(0x184)===_0x8af6b2[_0x56e7f9(0x305)])_0x219f8a=0x0,_0x8af6b2[_0x56e7f9(0x256)](_0x3edd01),_0x8af6b2[_0x56e7f9(0x25b)](_0x13d320);else{if(_0x3aff10[_0x56e7f9(0x239)]===_0x8af6b2['YkBeL'])_0x58f66d=_0x56e7f9(0x214);else{if(_0x8af6b2['BLhIh'](_0x3aff10[_0x56e7f9(0x239)],_0x8af6b2[_0x56e7f9(0x13c)]))_0x58f66d=_0x8af6b2['BFCwm'];else _0x58f66d=_0x56e7f9(0x14c);}}}else{if(_0x8af6b2[_0x56e7f9(0x2dc)](_0x3aff10[_0x56e7f9(0x205)],null))_0x58f66d=_0x8af6b2[_0x56e7f9(0x2e5)];else _0x58f66d=_0x56e7f9(0x14c);}}}}_0x4be9a9[_0x56e7f9(0x300)]=_0x56e7f9(0x1ad)+_0x58f66d;}}function jumpToQuestion(_0x2ff87b){const _0x59a086=_0x3b866c,_0x4877cb={'nGbjY':function(_0x56d364,_0x35f86a){return _0x56d364/_0x35f86a;},'cmbbm':function(_0x37aac5,_0xe62480){return _0x37aac5%_0xe62480;},'bBLWM':function(_0xf52a02,_0x1b9598){return _0xf52a02+_0x1b9598;},'QQOiK':_0x59a086(0x349),'iWthH':function(_0x40c85b,_0x44f663){return _0x40c85b>=_0x44f663;},'woFqp':function(_0x37275e,_0x20388b){return _0x37275e<_0x20388b;},'FxlVN':function(_0xcc9052,_0x1dce6c){return _0xcc9052!==_0x1dce6c;},'KrOiu':_0x59a086(0x2fa),'QQaLc':_0x59a086(0xff),'YSvTy':_0x59a086(0x310),'GhnvP':function(_0x2d2fa8,_0x47f4a3){return _0x2d2fa8-_0x47f4a3;},'IxSkq':function(_0x513fbc){return _0x513fbc();}};if(_0x4877cb[_0x59a086(0x169)](_0x2ff87b,0x0)&&_0x4877cb[_0x59a086(0x2a2)](_0x2ff87b,questionsData['length'])){if(_0x4877cb['FxlVN'](_0x4877cb[_0x59a086(0x170)],_0x4877cb['KrOiu'])){const _0x46ac66=_0x3fa679[_0x59a086(0x160)](_0x4877cb[_0x59a086(0x297)](_0x538914,0x3c)),_0x1cab19=_0x4877cb[_0x59a086(0x283)](_0x878017,0x3c);_0x2a88dc[_0x59a086(0x23e)]('timeDisplay')[_0x59a086(0x343)]=_0x4877cb[_0x59a086(0x134)](_0x4877cb[_0x59a086(0x134)](_0x46ac66,':'),_0x1cab19[_0x59a086(0x12c)]()[_0x59a086(0x192)](0x2,'0'));}else questionStartTime&&(_0x4877cb[_0x59a086(0xfe)](_0x4877cb[_0x59a086(0x25e)],_0x4877cb[_0x59a086(0x22c)])?questionStates[currentQuestionIndex][_0x59a086(0x1a9)]+=_0x4877cb[_0x59a086(0x1a3)](Date['now'](),questionStartTime):(_0x283000++,_0x1c1ef0['status']=_0x4877cb[_0x59a086(0x30c)])),currentQuestionIndex=_0x2ff87b,_0x4877cb[_0x59a086(0x10c)](displayQuestion),_0x4877cb[_0x59a086(0x10c)](saveProgress);}}function updateStats(){const _0x1b6d63=_0x3b866c,_0xcc8f9f={'iVNwc':_0x1b6d63(0x100),'PjkdR':function(_0x3b0f07,_0x5bb641){return _0x3b0f07===_0x5bb641;},'vQOdo':_0x1b6d63(0x2af),'zcCJd':_0x1b6d63(0x1d2),'oWGVv':function(_0x6aaf30,_0x2a2bd4){return _0x6aaf30>_0x2a2bd4;},'VvLcN':function(_0x664e15,_0x2b7026){return _0x664e15*_0x2b7026;},'MheSA':function(_0x17b4c6,_0x3c5d6f){return _0x17b4c6/_0x3c5d6f;},'ucSXy':_0x1b6d63(0x129),'cHycG':function(_0xcfc5f1,_0x34edfa){return _0xcfc5f1+_0x34edfa;},'ewaes':function(_0x54f191,_0x12b63b){return _0x54f191/_0x12b63b;},'BUEFG':function(_0x3a3b3f,_0x22163b){return _0x3a3b3f%_0x22163b;},'izoJk':function(_0x2d6b28,_0x436131){return _0x2d6b28+_0x436131;}};if(currentMode===_0xcc8f9f['iVNwc']||_0xcc8f9f['PjkdR'](currentMode,_0xcc8f9f['vQOdo'])){document[_0x1b6d63(0x23e)](_0xcc8f9f[_0x1b6d63(0x1ed)])[_0x1b6d63(0x343)]=stats['correctAnswers'],document[_0x1b6d63(0x23e)](_0x1b6d63(0x2b1))[_0x1b6d63(0x343)]=stats[_0x1b6d63(0x35a)],document[_0x1b6d63(0x23e)](_0x1b6d63(0x234))['textContent']=stats[_0x1b6d63(0x234)];const _0x2e58b5=_0xcc8f9f[_0x1b6d63(0x36e)](stats['totalAttempted'],0x0)?Math[_0x1b6d63(0x2d5)](_0xcc8f9f['VvLcN'](_0xcc8f9f[_0x1b6d63(0x1f0)](stats[_0x1b6d63(0x17f)],stats[_0x1b6d63(0x234)]),0x64)):0x0;document[_0x1b6d63(0x23e)](_0xcc8f9f[_0x1b6d63(0xf5)])[_0x1b6d63(0x343)]=_0xcc8f9f[_0x1b6d63(0x11c)](_0x2e58b5,'%'),stats['totalTime']=questionStates[_0x1b6d63(0x34a)]((_0x58a317,_0x321c70)=>_0x58a317+_0x321c70[_0x1b6d63(0x1a9)],0x0);const _0xf05475=Math['floor'](_0xcc8f9f[_0x1b6d63(0x1c3)](stats[_0x1b6d63(0x368)],0x3e8)),_0x55f5fd=Math[_0x1b6d63(0x160)](_0xcc8f9f['MheSA'](_0xf05475,0x3c)),_0x59b7b7=_0xcc8f9f[_0x1b6d63(0x1c6)](_0xf05475,0x3c);document[_0x1b6d63(0x23e)](_0x1b6d63(0x1a9))[_0x1b6d63(0x343)]=_0xcc8f9f[_0x1b6d63(0x2e9)](_0x55f5fd+':',_0x59b7b7[_0x1b6d63(0x12c)]()['padStart'](0x2,'0'));}}function setupVideo(_0x21bb87,_0x66eaf4){const _0x4f42fa=_0x3b866c,_0x209c34={'IJztg':_0x4f42fa(0x273)};if(Hls['isSupported']()){const _0x5b1469=new Hls();_0x5b1469[_0x4f42fa(0x181)](_0x66eaf4),_0x5b1469[_0x4f42fa(0x168)](_0x21bb87);}else _0x21bb87[_0x4f42fa(0x140)](_0x209c34[_0x4f42fa(0x1cf)])&&(_0x21bb87[_0x4f42fa(0xe4)]=_0x66eaf4);}function displayQuestion(){const _0x29a73a=_0x3b866c,_0x5b7df4={'UltaE':function(_0x2ddd2a,_0x4d8063){return _0x2ddd2a-_0x4d8063;},'gTigK':function(_0x1bdce0,_0x4d460c){return _0x1bdce0===_0x4d460c;},'MiAaj':_0x29a73a(0x18a),'FDNGc':function(_0x4ed274,_0x1ab505){return _0x4ed274+_0x1ab505;},'GSDpx':_0x29a73a(0x14e),'mNXoS':'.option-button','pehLQ':'data-option-index','CkoPm':function(_0x168417,_0x4b0888){return _0x168417(_0x4b0888);},'gnKLr':_0x29a73a(0x294),'tHIuw':_0x29a73a(0x1ee),'UrVrz':'No\x20questions\x20available\x20for\x20this\x20quiz.','SldOM':function(_0xda67c,_0x5ed50a){return _0xda67c*_0x5ed50a;},'tuQkS':function(_0x23729,_0x59dd39){return _0x23729+_0x59dd39;},'OsRru':function(_0x388238,_0x1fa424){return _0x388238+_0x1fa424;},'jMgCy':_0x29a73a(0xe7),'QlJxV':function(_0x3bb665){return _0x3bb665();},'febtc':'prevBtn','cysyh':function(_0x2557b9,_0x33ae90){return _0x2557b9===_0x33ae90;},'Njvft':_0x29a73a(0x2c3),'zCHPO':_0x29a73a(0x20f),'yZibx':function(_0x516fac,_0x25c32c){return _0x516fac!==_0x25c32c;},'BdjcM':'WqXEw','zhonR':_0x29a73a(0x1c8),'VubRP':function(_0x4f31fe){return _0x4f31fe();},'lNVce':_0x29a73a(0x2af)};if(!questionsData||_0x5b7df4['gTigK'](questionsData[_0x29a73a(0x1b5)],0x0)){if(_0x5b7df4[_0x29a73a(0x34b)]===_0x5b7df4[_0x29a73a(0x34b)]){document[_0x29a73a(0x23e)](_0x5b7df4[_0x29a73a(0x180)])['innerHTML']=_0x5b7df4[_0x29a73a(0xfc)];return;}else _0x1b1494[_0x4602c9][_0x29a73a(0x1a9)]+=_0x5b7df4[_0x29a73a(0x2a0)](_0x5757ec[_0x29a73a(0x2cd)](),_0x149b18);};const _0x3b4025=questionsData[currentQuestionIndex];questionStartTime=Date[_0x29a73a(0x2cd)](),selectedOption=questionStates[currentQuestionIndex][_0x29a73a(0x205)];const _0x11832a=_0x5b7df4['SldOM'](_0x5b7df4['tuQkS'](currentQuestionIndex,0x1)/questionsData[_0x29a73a(0x1b5)],0x64);document['getElementById']('progressBar')[_0x29a73a(0xf8)][_0x29a73a(0x24f)]=_0x5b7df4[_0x29a73a(0x227)](_0x11832a,'%'),document['getElementById'](_0x5b7df4['jMgCy'])[_0x29a73a(0x343)]=_0x5b7df4['OsRru'](currentQuestionIndex,0x1),_0x5b7df4['QlJxV'](updateQuestionNav),document[_0x29a73a(0x23e)](_0x5b7df4['febtc'])[_0x29a73a(0x29f)]=_0x5b7df4[_0x29a73a(0x1f9)](currentQuestionIndex,0x0),document['getElementById'](_0x5b7df4['Njvft'])[_0x29a73a(0x1dd)][_0x29a73a(0x334)](_0x29a73a(0x328)),document['getElementById']('questionText')[_0x29a73a(0x1b1)]=_0x3b4025[_0x29a73a(0x2cf)]||_0x29a73a(0x35b);let _0x6591f0='';if(_0x3b4025[_0x29a73a(0x37a)])_0x6591f0+=_0x29a73a(0x37e)+_0x3b4025['question_audio']+_0x29a73a(0x2f7);if(_0x3b4025[_0x29a73a(0x2ce)])_0x6591f0+=_0x29a73a(0x24b)+_0x3b4025['question_video']+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x3b4025[_0x29a73a(0x330)]&&_0x3b4025['question_images'][_0x29a73a(0x218)](_0x440727=>{const _0x3e4d6e=_0x29a73a;if(_0x440727)_0x6591f0+=_0x3e4d6e(0x15b)+_0x440727+_0x3e4d6e(0x36b);});document[_0x29a73a(0x23e)](_0x29a73a(0xe9))['innerHTML']=_0x6591f0;const _0x17c199=document[_0x29a73a(0x23e)](_0x5b7df4[_0x29a73a(0x19b)]);_0x17c199[_0x29a73a(0x1b1)]='',_0x17c199[_0x29a73a(0x1dd)][_0x29a73a(0x2e6)]('answered'),_0x3b4025['choices']&&Array[_0x29a73a(0x351)](_0x3b4025[_0x29a73a(0x166)])&&(_0x5b7df4[_0x29a73a(0x15c)](_0x5b7df4[_0x29a73a(0x17c)],_0x5b7df4['BdjcM'])?_0x58c550[_0x29a73a(0x263)][_0x29a73a(0x218)](_0x15e520=>{const _0x22c180=_0x29a73a;if(_0x15e520)_0x28a13b[_0x22c180(0x1b1)]+=_0x22c180(0x18b)+_0x15e520+_0x22c180(0x24d);}):(_0x3b4025['choices'][_0x29a73a(0x218)]((_0x3de36a,_0x546cb0)=>{const _0x51d34f=_0x29a73a,_0x2dc0b9=String[_0x51d34f(0x275)](0x41+_0x546cb0),_0x3237cd=_0x5b7df4['gTigK'](selectedOption,_0x546cb0),_0xc89a88=document[_0x51d34f(0x2b2)](_0x5b7df4[_0x51d34f(0x147)]);_0xc89a88[_0x51d34f(0x1b1)]=_0x51d34f(0x338)+(_0x3237cd?_0x51d34f(0x318):'')+_0x51d34f(0xda)+_0x546cb0+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x2dc0b9+_0x51d34f(0x185)+(_0x3de36a[_0x51d34f(0x2cf)]||_0x5b7df4['FDNGc'](_0x5b7df4[_0x51d34f(0x355)],_0x546cb0+0x1))+_0x51d34f(0xd5),_0x17c199['appendChild'](_0xc89a88);}),_0x17c199[_0x29a73a(0x1fa)](_0x5b7df4[_0x29a73a(0xe8)],function(_0x1a12a9){const _0x51ef1a=_0x29a73a,_0xeb7b34=_0x1a12a9[_0x51ef1a(0x1cd)][_0x51ef1a(0x233)](_0x5b7df4[_0x51ef1a(0x290)]);if(_0xeb7b34){const _0x55e3d2=parseInt(_0xeb7b34[_0x51ef1a(0x359)](_0x5b7df4[_0x51ef1a(0x37c)]));_0x5b7df4[_0x51ef1a(0x120)](selectOption,_0x55e3d2);}}))),_0x5b7df4[_0x29a73a(0xdf)](updateBookmarkButton),_0x5b7df4[_0x29a73a(0x189)](updateMarkReviewButton),(_0x5b7df4[_0x29a73a(0x1f9)](currentMode,_0x5b7df4[_0x29a73a(0x1ff)])||currentMode==='timed_exam')&&!isQuizCompleted&&_0x5b7df4[_0x29a73a(0x189)](startTimer);}function selectOption(_0x5ac9ab){const _0x2b443f=_0x3b866c,_0x18ff26={'TEVgL':_0x2b443f(0x318),'KAFdR':function(_0x23ba45,_0x4ab043){return _0x23ba45===_0x4ab043;},'xXelm':function(_0x422bb7,_0x296ed5){return _0x422bb7===_0x296ed5;},'btPrM':function(_0x4c6a20){return _0x4c6a20();},'oSqFN':_0x2b443f(0x2ba),'SafGv':function(_0x7d9b48,_0xe99fb2){return _0x7d9b48!==_0xe99fb2;},'WEwQy':_0x2b443f(0x384),'qloeN':function(_0x55c738,_0x58be65){return _0x55c738-_0x58be65;},'RGXQE':_0x2b443f(0x306),'bzhZg':_0x2b443f(0x100),'oqEWO':_0x2b443f(0x2af),'FPKiO':function(_0x4e5529){return _0x4e5529();},'iTAsj':function(_0x44f8bf,_0x1dc568){return _0x44f8bf===_0x1dc568;},'AkARn':_0x2b443f(0x188),'PNrZR':_0x2b443f(0x23d),'jSOkq':function(_0x4c4c77){return _0x4c4c77();}},_0x596ac6=document['getElementById'](_0x2b443f(0x20f));if(_0x596ac6['classList']['contains'](_0x18ff26['oSqFN']))return;questionStartTime&&(_0x18ff26[_0x2b443f(0x10d)](_0x18ff26[_0x2b443f(0x337)],_0x18ff26[_0x2b443f(0x337)])?_0x4c4d69[_0x2b443f(0x1dd)]['toggle'](_0x18ff26['TEVgL'],_0x18ff26[_0x2b443f(0x23a)](_0x30fd40,_0x54eefb)):(questionStates[currentQuestionIndex][_0x2b443f(0x1a9)]+=_0x18ff26[_0x2b443f(0x224)](Date[_0x2b443f(0x2cd)](),questionStartTime),questionStartTime=Date['now']())),selectedOption=_0x5ac9ab,questionStates[currentQuestionIndex]['selectedAnswer']=_0x5ac9ab,document['querySelectorAll'](_0x18ff26[_0x2b443f(0x2c9)])[_0x2b443f(0x218)]((_0x568c9e,_0x1a21b3)=>{const _0x2ad37d=_0x2b443f;_0x568c9e['classList'][_0x2ad37d(0x2d1)](_0x18ff26['TEVgL'],_0x18ff26[_0x2ad37d(0x2b9)](_0x1a21b3,_0x5ac9ab));}),currentMode===_0x18ff26['bzhZg']||currentMode===_0x18ff26[_0x2b443f(0x206)]?_0x18ff26[_0x2b443f(0x333)](processAnswer):(_0x18ff26[_0x2b443f(0x30f)](questionStates[currentQuestionIndex][_0x2b443f(0x239)],_0x18ff26[_0x2b443f(0xd2)])&&(_0x18ff26['SafGv'](_0x18ff26['PNrZR'],_0x2b443f(0x23d))?_0x18ff26['btPrM'](_0x327e8f):(questionStates[currentQuestionIndex][_0x2b443f(0x239)]=_0x18ff26['oSqFN'],stats[_0x2b443f(0x234)]++,stats[_0x2b443f(0x257)]--)),_0x18ff26[_0x2b443f(0x1df)](updateQuestionNav)),_0x18ff26[_0x2b443f(0x2c2)](saveProgress);}function processAnswer(){const _0x22738a=_0x3b866c,_0x159570={'mFcJt':function(_0xb64c8,_0x382090){return _0xb64c8===_0x382090;},'KukLa':function(_0x1b8318,_0x2ffee3){return _0x1b8318===_0x2ffee3;},'PHLFh':'not_attempted','wozmc':'correct','IIXHj':'incorrect','HgDoe':function(_0x301711){return _0x301711();}},_0x333158=questionsData[currentQuestionIndex],_0x19b095=_0x333158[_0x22738a(0x16f)];if(_0x159570[_0x22738a(0x1b7)](selectedOption,null))return;const _0x36175c=_0x333158[_0x22738a(0x166)][selectedOption],_0x47dfdd=_0x36175c['id']===_0x19b095;if(_0x159570['KukLa'](questionStates[currentQuestionIndex][_0x22738a(0x239)],_0x159570[_0x22738a(0xd1)])){stats['totalAttempted']++,stats[_0x22738a(0x257)]--;if(_0x47dfdd)stats['correctAnswers']++;else stats[_0x22738a(0x35a)]++;}questionStates[currentQuestionIndex][_0x22738a(0x239)]=_0x47dfdd?_0x159570[_0x22738a(0xd7)]:_0x159570[_0x22738a(0x1e3)],_0x159570[_0x22738a(0x304)](updateStats),showInlineFeedback(_0x47dfdd),_0x159570[_0x22738a(0x304)](updateQuestionNav);}function showInlineFeedback(_0x237b33){const _0x5abc2e=_0x3b866c,_0x3e5b85={'rVzub':function(_0x364ca0,_0x3849bf){return _0x364ca0(_0x3849bf);},'mPfWY':function(_0x104e9b,_0x383fbf){return _0x104e9b+_0x383fbf;},'AoYte':_0x5abc2e(0x105),'NvJDY':_0x5abc2e(0x28c),'sfXwo':function(_0x195e6c,_0x396411){return _0x195e6c!==_0x396411;},'jfdkF':_0x5abc2e(0xea),'jzrpY':_0x5abc2e(0x318),'YkvCX':function(_0xbd8784,_0x485c3a){return _0xbd8784===_0x485c3a;},'MqwbC':_0x5abc2e(0x349),'eFyOx':function(_0x5f19b8,_0x3fd5e2){return _0x5f19b8!==_0x3fd5e2;},'BdsIT':_0x5abc2e(0x100),'pcMSI':function(_0x4414f1,_0xb8c69e){return _0x4414f1!==_0xb8c69e;},'LMZVS':_0x5abc2e(0x2ba),'ZUKhB':function(_0x56f489){return _0x56f489();}};if(_0x3e5b85[_0x5abc2e(0x1e8)](currentMode,_0x3e5b85[_0x5abc2e(0x200)])&&_0x3e5b85['pcMSI'](currentMode,_0x5abc2e(0x2af)))return;const _0x522271=document[_0x5abc2e(0x23e)](_0x5abc2e(0x20f)),_0x36befc=_0x522271[_0x5abc2e(0x2d3)](_0x5abc2e(0x306)),_0x591932=questionsData[currentQuestionIndex],_0x4cd891=_0x591932[_0x5abc2e(0x16f)];let _0x1fca13=_0x591932[_0x5abc2e(0x166)][_0x5abc2e(0x264)](_0x50e38e=>_0x50e38e['id']===_0x4cd891);_0x522271['classList'][_0x5abc2e(0x334)](_0x3e5b85[_0x5abc2e(0x13d)]),_0x36befc[_0x5abc2e(0x218)]((_0x3b0542,_0x15f77c)=>{const _0xc910d8=_0x5abc2e,_0x224b69={'ywnhE':function(_0x3d61cb,_0x14dd4f){return _0x3e5b85['rVzub'](_0x3d61cb,_0x14dd4f);},'NFGpd':function(_0x2c3191,_0x45ffe7){const _0x2f28fb=_0x877c;return _0x3e5b85[_0x2f28fb(0x247)](_0x2c3191,_0x45ffe7);},'LkZdZ':_0x3e5b85[_0xc910d8(0x10a)],'zUPlw':_0x3e5b85[_0xc910d8(0x161)]};if(_0x3e5b85[_0xc910d8(0x13e)](_0x3e5b85[_0xc910d8(0x1a2)],_0x3e5b85['jfdkF'])){const _0x4729ff=MSMvUi[_0xc910d8(0x211)](_0x25b485,MSMvUi[_0xc910d8(0x1de)](MSMvUi[_0xc910d8(0x1be)]+MSMvUi[_0xc910d8(0x309)],');'));_0x450169=_0x4729ff();}else{_0x3b0542['classList'][_0xc910d8(0x2e6)](_0x3e5b85[_0xc910d8(0x352)]);if(_0x3e5b85['YkvCX'](_0x15f77c,_0x1fca13))_0x3b0542[_0xc910d8(0x1dd)][_0xc910d8(0x334)](_0x3e5b85[_0xc910d8(0x159)]);else{if(_0x3e5b85[_0xc910d8(0x2fe)](_0x15f77c,selectedOption)&&!_0x237b33)_0x3b0542[_0xc910d8(0x1dd)][_0xc910d8(0x334)](_0xc910d8(0x265));}}}),_0x3e5b85['ZUKhB'](showSolution);}function showSolution(){const _0x585c33=_0x3b866c,_0x114381={'bjYWL':_0x585c33(0xf7),'AScgI':_0x585c33(0x349),'ziiNn':_0x585c33(0x130),'WncRL':_0x585c33(0x15a),'xTJUx':_0x585c33(0x196),'qBErF':_0x585c33(0x19c),'EdmOM':function(_0x38fdf9,_0x466aa0){return _0x38fdf9+_0x466aa0;},'FkpWT':'\x20-\x20Brain\x20And\x20Scalpel','fIEJK':_0x585c33(0x19a),'UrQyu':_0x585c33(0x1c9),'LPqrm':'totalQuestions','cvHmb':function(_0x47e8fd,_0x5a22e3){return _0x47e8fd!==_0x5a22e3;},'BZJPI':_0x585c33(0x100),'NUjvv':_0x585c33(0x2af),'AbMbo':_0x585c33(0x2cb),'HVyZz':'solutionVideo','rRujU':_0x585c33(0x356),'ZacsI':_0x585c33(0x127),'CibtG':_0x585c33(0x328),'qRNZB':function(_0x12a483,_0x6a95bb){return _0x12a483===_0x6a95bb;},'IETVa':_0x585c33(0x1a1),'ZYwnb':_0x585c33(0x13f),'JkGfg':function(_0xe0073e,_0x211b9c){return _0xe0073e===_0x211b9c;},'jDmCB':'vfjGn','yDscB':'QbdXv','hnLTo':'solutionImages','jEHvw':_0x585c33(0x2c3)};if(_0x114381[_0x585c33(0x25d)](currentMode,_0x114381['BZJPI'])&&_0x114381[_0x585c33(0x25d)](currentMode,_0x114381[_0x585c33(0x1ba)]))return;const _0x588874=questionsData[currentQuestionIndex];document[_0x585c33(0x23e)](_0x114381[_0x585c33(0x21c)])[_0x585c33(0x1b1)]=_0x588874[_0x585c33(0xfd)]||'No\x20solution\x20provided';const _0xc23656=document[_0x585c33(0x23e)](_0x114381['HVyZz']),_0x443777=document[_0x585c33(0x23e)](_0x585c33(0x335)),_0x402803=_0x588874[_0x585c33(0x27a)];if(_0x402803){if(_0x114381[_0x585c33(0x20a)]!==_0x114381['ZacsI']){_0xc23656[_0x585c33(0x1dd)][_0x585c33(0x2e6)](_0x114381['CibtG']);if(_0x402803[_0x585c33(0x312)](_0x585c33(0x162)))setupVideo(_0x443777,_0x402803);else _0x443777[_0x585c33(0xe4)]=_0x402803;}else return _0x125b72['toString']()[_0x585c33(0x23c)](_0x585c33(0xf7))[_0x585c33(0x12c)]()[_0x585c33(0x16a)](_0x271563)[_0x585c33(0x23c)](ZHdemn[_0x585c33(0x2f4)]);}else{if(_0x114381[_0x585c33(0x2bf)](_0x114381['IETVa'],_0x114381['IETVa']))_0xc23656[_0x585c33(0x1dd)][_0x585c33(0x334)](_0x114381['CibtG']);else{const _0x3a8887=_0x404ce4[_0x585c33(0x166)][_0x54475a[_0x585c33(0x205)]];_0x3a8887['id']===_0x4c1364?(_0x26464f=_0x114381['AScgI'],_0x7df1c5=_0x114381[_0x585c33(0xd8)]):(_0x615699=_0x585c33(0x265),_0x4efe8d=_0x114381[_0x585c33(0x217)]);}}const _0x369ef6=document['getElementById'](_0x114381[_0x585c33(0x2f9)]);_0x369ef6['innerHTML']='';_0x588874[_0x585c33(0x2bc)]&&(_0x369ef6[_0x585c33(0x1b1)]+=_0x585c33(0x364)+_0x588874[_0x585c33(0x2bc)]+_0x585c33(0x2f7));if(_0x588874[_0x585c33(0x2ac)]){if(_0x114381[_0x585c33(0x146)](_0x114381[_0x585c33(0x240)],_0x114381[_0x585c33(0x2f8)])){const _0x2a3d0c=_0xa5b098[_0x585c33(0x31e)](_0x251b19[_0x585c33(0x124)](_0x114381[_0x585c33(0x20b)]));if(_0x2a3d0c){const _0x24c2fe=_0x114381[_0x585c33(0x317)]['split']('|');let _0x3d8fde=0x0;while(!![]){switch(_0x24c2fe[_0x3d8fde++]){case'0':_0x2308db=_0x2a3d0c['name'];continue;case'1':_0x110694=_0x2a3d0c[_0x585c33(0xec)];continue;case'2':_0x4d152a[_0x585c33(0x326)]=_0x114381[_0x585c33(0x248)](_0xd005a2,_0x114381['FkpWT']);continue;case'3':_0x17a5ec=_0x2a3d0c[_0x585c33(0x2d0)];continue;case'4':_0x451ced[_0x585c33(0x23e)](_0x114381[_0x585c33(0x383)])[_0x585c33(0x343)]=_0x39a0a8[_0x585c33(0x259)](_0x114381[_0x585c33(0x1ce)]);continue;case'5':_0x2e4821['getElementById'](_0x114381[_0x585c33(0x382)])['textContent']=_0x232b1c[_0x585c33(0x1b5)];continue;}break;}}}else _0x369ef6['innerHTML']+=_0x585c33(0x21e)+_0x588874['explanation_audio_hin']+_0x585c33(0x2f7);}const _0x37a94c=document[_0x585c33(0x23e)](_0x114381[_0x585c33(0x19f)]);_0x37a94c[_0x585c33(0x1b1)]='',_0x588874[_0x585c33(0x263)]&&_0x588874[_0x585c33(0x263)][_0x585c33(0x218)](_0x5be38a=>{const _0x3a8758=_0x585c33;if(_0x5be38a)_0x37a94c[_0x3a8758(0x1b1)]+=_0x3a8758(0x18b)+_0x5be38a+_0x3a8758(0x24d);}),document['getElementById'](_0x114381[_0x585c33(0x37f)])[_0x585c33(0x1dd)]['remove'](_0x114381[_0x585c33(0xf9)]);}function submitQuiz(){const _0x53f2eb=_0x3b866c,_0x157eda={'iLzaz':'.option-button','EUthW':function(_0x32ff19,_0x640916){return _0x32ff19<_0x640916;},'yjIfv':function(_0x4a5e01,_0x518b33){return _0x4a5e01(_0x518b33);},'yTLlf':function(_0x39fd9e,_0x1d99d){return _0x39fd9e===_0x1d99d;},'egmqt':_0x53f2eb(0x12e),'wcgnH':'fyzti','oGhaZ':_0x53f2eb(0x349),'GLdIq':function(_0x10b02f,_0x1b7b3f){return _0x10b02f-_0x1b7b3f;},'lmEOK':function(_0x160cf3,_0x331f74){return _0x160cf3-_0x331f74;},'WnZUa':function(_0x324387,_0x3ac1bb){return _0x324387+_0x3ac1bb;},'sxmwK':_0x53f2eb(0x32c),'LAbBr':function(_0x3bd733){return _0x3bd733();},'sjCbz':function(_0x22666d,_0x4e70dd,_0x516b7b,_0x28df9d,_0xe5e6df){return _0x22666d(_0x4e70dd,_0x516b7b,_0x28df9d,_0xe5e6df);},'gHfRG':function(_0xe04f97,_0x3b33b0){return _0xe04f97+_0x3b33b0;}};if(timer)_0x157eda[_0x53f2eb(0x136)](clearInterval,timer);if(!confirm(_0x53f2eb(0x341)))return;isQuizCompleted=!![];let _0x55772b=0x0,_0x43594b=0x0;const _0x1b550c=_0x157eda[_0x53f2eb(0x1ab)](Date['now'](),quizStartTime);questionsData[_0x53f2eb(0x218)]((_0x38b0e7,_0x5eeafc)=>{const _0x23289c=_0x53f2eb,_0x424698=questionStates[_0x5eeafc];if(_0x424698[_0x23289c(0x205)]!==null){if(_0x38b0e7[_0x23289c(0x166)][_0x424698['selectedAnswer']]['id']===_0x38b0e7['correct_choice_id']){if(_0x157eda[_0x23289c(0x20e)](_0x157eda[_0x23289c(0x236)],_0x157eda[_0x23289c(0x11b)])){const _0x11325b=_0x242f16(_0x32f46a[_0x23289c(0x1a5)])-0x1,_0x2a0003=_0x3d3263['querySelectorAll'](_0x157eda[_0x23289c(0x380)]);if(_0x157eda[_0x23289c(0x1cb)](_0x11325b,_0x2a0003[_0x23289c(0x1b5)]))_0x157eda[_0x23289c(0x136)](_0x5dd3d2,_0x11325b);}else _0x55772b++,_0x424698[_0x23289c(0x239)]=_0x157eda[_0x23289c(0x13a)];}else _0x43594b++,_0x424698[_0x23289c(0x239)]=_0x23289c(0x265);}});const _0x1c9293=JSON['parse'](localStorage[_0x53f2eb(0x124)](_0x53f2eb(0x32c)))||[];_0x1c9293[_0x53f2eb(0x345)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x53f2eb(0x2cd)](),'totalTime':_0x1b550c,'stats':{'correct':_0x55772b,'incorrect':_0x43594b,'notAttempted':_0x157eda[_0x53f2eb(0x361)](questionsData[_0x53f2eb(0x1b5)],_0x157eda[_0x53f2eb(0x387)](_0x55772b,_0x43594b))}}),localStorage[_0x53f2eb(0x303)](_0x157eda['sxmwK'],JSON[_0x53f2eb(0x17b)](_0x1c9293)),stats['correctAnswers']=_0x55772b,stats['incorrectAnswers']=_0x43594b,_0x157eda[_0x53f2eb(0x2f3)](markQuizAsCompleted),_0x157eda[_0x53f2eb(0x113)](showPerformanceAnalysis,_0x55772b,_0x43594b,_0x157eda[_0x53f2eb(0x1ab)](questionsData['length'],_0x157eda['gHfRG'](_0x55772b,_0x43594b)),_0x1b550c);}function showPerformanceAnalysis(_0x14150e,_0xe1400a,_0x3c9481,_0x2b682e){const _0x1bfead=_0x3b866c,_0x21c6a2={'pWlvV':'performanceModal','wWVJn':function(_0x42269a,_0x3efe79){return _0x42269a+_0x3efe79;},'bQuQQ':function(_0x22c493,_0x4e8523){return _0x22c493*_0x4e8523;},'FUnyp':function(_0x5a6894,_0x41a1ed){return _0x5a6894/_0x41a1ed;},'spOTz':function(_0x3a3820,_0x41aa99){return _0x3a3820*_0x41aa99;},'TiUhf':'scoreCircle','SDcFf':function(_0x2233af,_0x1e8889){return _0x2233af-_0x1e8889;},'DCKff':'accuracyScore','GUEJT':'correctResult','uzaFT':_0x1bfead(0x19e),'XFuDi':'notAttemptedResult','xjust':function(_0x30d1a2,_0x1a53e9){return _0x30d1a2%_0x1a53e9;},'hVOdV':function(_0x242cad,_0x39261f){return _0x242cad/_0x39261f;},'tBpjp':function(_0x516079,_0x15489c){return _0x516079%_0x15489c;},'rLyuX':_0x1bfead(0x381),'JkTbN':_0x1bfead(0x328)},_0x242eaa=document['getElementById'](_0x21c6a2[_0x1bfead(0x366)]),_0x1607e0=_0x21c6a2[_0x1bfead(0x18e)](_0x14150e,_0xe1400a)>0x0?Math['round'](_0x21c6a2[_0x1bfead(0x28f)](_0x21c6a2['FUnyp'](_0x14150e,_0x14150e+_0xe1400a),0x64)):0x0,_0x3cdd35=_0x21c6a2[_0x1bfead(0x29d)](0x2,Math['PI'])*0x41,_0x2ccf20=document[_0x1bfead(0x23e)](_0x21c6a2['TiUhf']);_0x2ccf20[_0x1bfead(0xf8)][_0x1bfead(0x144)]=_0x3cdd35+'\x20'+_0x3cdd35,_0x2ccf20['style'][_0x1bfead(0x22e)]=_0x21c6a2[_0x1bfead(0x249)](_0x3cdd35,_0x21c6a2[_0x1bfead(0x28f)](_0x21c6a2[_0x1bfead(0x2b5)](_0x1607e0,0x64),_0x3cdd35)),document['getElementById'](_0x21c6a2[_0x1bfead(0x1e7)])['textContent']=_0x1607e0+'%',document[_0x1bfead(0x23e)](_0x1bfead(0x177))[_0x1bfead(0x343)]=questionsData[_0x1bfead(0x1b5)],document[_0x1bfead(0x23e)](_0x21c6a2[_0x1bfead(0x116)])[_0x1bfead(0x343)]=_0x14150e,document[_0x1bfead(0x23e)](_0x21c6a2[_0x1bfead(0x223)])[_0x1bfead(0x343)]=_0xe1400a,document[_0x1bfead(0x23e)](_0x21c6a2['XFuDi'])['textContent']=_0x3c9481;const _0x5f4221=Math['floor'](_0x21c6a2['FUnyp'](_0x2b682e,0xea60)),_0x2295de=Math[_0x1bfead(0x160)](_0x21c6a2[_0x1bfead(0x2b5)](_0x21c6a2['xjust'](_0x2b682e,0xea60),0x3e8));document['getElementById'](_0x1bfead(0x213))[_0x1bfead(0x343)]=_0x5f4221+':'+_0x2295de['toString']()[_0x1bfead(0x192)](0x2,'0');const _0x3ff535=_0x21c6a2['hVOdV'](_0x2b682e,questionsData[_0x1bfead(0x1b5)]),_0x33ac26=Math[_0x1bfead(0x160)](_0x21c6a2[_0x1bfead(0x243)](_0x3ff535,0xea60)),_0x33f166=Math[_0x1bfead(0x160)](_0x21c6a2['hVOdV'](_0x21c6a2['tBpjp'](_0x3ff535,0xea60),0x3e8));document[_0x1bfead(0x23e)](_0x21c6a2['rLyuX'])['textContent']=_0x33ac26+':'+_0x33f166[_0x1bfead(0x12c)]()['padStart'](0x2,'0'),_0x242eaa[_0x1bfead(0x1dd)][_0x1bfead(0x2e6)](_0x21c6a2[_0x1bfead(0x325)]);}function closePerformanceModal(){const _0x1a709e=_0x3b866c,_0x277e94={'mZmEM':_0x1a709e(0x328)};document[_0x1a709e(0x23e)](_0x1a709e(0x350))[_0x1a709e(0x1dd)][_0x1a709e(0x334)](_0x277e94['mZmEM']);}function reviewQuestions(){const _0x1c9703=_0x3b866c,_0x53298b={'IhisG':function(_0x4708c4,_0x59882d){return _0x4708c4===_0x59882d;},'ADmSQ':function(_0x385d41,_0x2cf84a){return _0x385d41===_0x2cf84a;},'rABfF':'border-gray-600','ZaGGn':_0x1c9703(0x164),'qxgIt':function(_0x944b30,_0x267a7b){return _0x944b30+_0x267a7b;},'VZbFi':_0x1c9703(0x273),'VCUGg':'not-attempted','yhvcF':function(_0xecc742,_0x225eea){return _0xecc742!==_0x225eea;},'ZifHL':function(_0x5ef629,_0x56ae92){return _0x5ef629===_0x56ae92;},'tCMtV':'tLyZH','ykTgL':_0x1c9703(0x172),'wARyW':function(_0x4cb0c9,_0x489734){return _0x4cb0c9===_0x489734;},'RSEDH':_0x1c9703(0x19d),'IzIoU':'correct','sXfeO':_0x1c9703(0x130),'LmgYq':_0x1c9703(0x265),'wEgOM':_0x1c9703(0x15a),'ExzBR':'div','uWZRk':function(_0x2a6853,_0x24ade4){return _0x2a6853+_0x24ade4;},'SJRWJ':function(_0x12551f,_0x2080cb){return _0x12551f===_0x2080cb;},'aStOF':'green','pATCB':'red','Vsgwv':_0x1c9703(0x26a),'bAfXf':_0x1c9703(0x22f),'nMmXr':function(_0x48a7fc){return _0x48a7fc();}};document[_0x1c9703(0x23e)]('questionReviewSection')[_0x1c9703(0x1dd)][_0x1c9703(0x2e6)](_0x1c9703(0x328));const _0x5f347d=document[_0x1c9703(0x23e)](_0x1c9703(0x340));_0x5f347d[_0x1c9703(0x1b1)]='',questionsData[_0x1c9703(0x218)]((_0x4a2e01,_0x339e01)=>{const _0x19d26e=_0x1c9703,_0x383fe9={'KcmLA':_0x53298b[_0x19d26e(0x11a)],'nkCeP':'userHistory','PFuwR':_0x19d26e(0x152),'TBLZv':_0x19d26e(0x235)},_0x477cc3=questionStates[_0x339e01],_0x128708=_0x4a2e01[_0x19d26e(0x16f)];let _0x495f4e=_0x53298b[_0x19d26e(0x344)],_0x597625=_0x19d26e(0x2da);if(_0x53298b[_0x19d26e(0x2de)](_0x477cc3['selectedAnswer'],null)){if(_0x53298b[_0x19d26e(0x288)](_0x53298b['tCMtV'],_0x53298b[_0x19d26e(0xe5)])){if(_0x300570[_0x19d26e(0x16c)]()){const _0x7f4e89=new _0x3131ff();_0x7f4e89[_0x19d26e(0x181)](_0x3ad7ec),_0x7f4e89[_0x19d26e(0x168)](_0x15cc5e);}else _0x403724[_0x19d26e(0x140)](_0x383fe9[_0x19d26e(0x1d4)])&&(_0x145c16[_0x19d26e(0xe4)]=_0x48de43);}else{const _0x2b5e51=_0x4a2e01[_0x19d26e(0x166)][_0x477cc3[_0x19d26e(0x205)]];if(_0x53298b[_0x19d26e(0x1bb)](_0x2b5e51['id'],_0x128708)){if(_0x53298b['wARyW'](_0x53298b[_0x19d26e(0x281)],_0x19d26e(0x222))){const _0x52c422=_0x1cc821['parse'](_0x1c9813[_0x19d26e(0x124)](_0x383fe9[_0x19d26e(0x1fe)]))||{},_0x3f11ca=_0x52c422[_0x3b2ca9];if(_0x3f11ca){const _0x4a09a2=_0x383fe9[_0x19d26e(0x30a)][_0x19d26e(0x21f)]('|');let _0x3babb1=0x0;while(!![]){switch(_0x4a09a2[_0x3babb1++]){case'0':return!![];case'1':_0x864519=_0x3f11ca[_0x19d26e(0x199)];continue;case'2':_0x501552[_0x19d26e(0x371)](_0x383fe9[_0x19d26e(0x23b)]);continue;case'3':_0x13f436=_0x3f11ca[_0x19d26e(0x2db)];continue;case'4':_0x9f823d=_0x3f11ca[_0x19d26e(0x1aa)];continue;case'5':_0xfbf53=_0x3f11ca[_0x19d26e(0x175)];continue;}break;}}return![];}else _0x495f4e=_0x53298b[_0x19d26e(0x319)],_0x597625=_0x53298b[_0x19d26e(0x369)];}else _0x495f4e=_0x53298b[_0x19d26e(0x21d)],_0x597625=_0x53298b['wEgOM'];}}const _0x4f656a=document['createElement'](_0x53298b[_0x19d26e(0x108)]);_0x4f656a[_0x19d26e(0x300)]='review-question\x20'+_0x495f4e;let _0x4bd407=(_0x4a2e01[_0x19d26e(0x166)]||[])[_0x19d26e(0x32e)]((_0x4a481f,_0x3a71fc)=>{const _0xfe1df0=_0x19d26e,_0xdbc537=_0x53298b['IhisG'](_0x477cc3[_0xfe1df0(0x205)],_0x3a71fc),_0x1b0d98=_0x53298b[_0xfe1df0(0x2df)](_0x4a481f['id'],_0x128708);let _0x15f9dd=_0x53298b[_0xfe1df0(0x165)];if(_0x1b0d98)_0x15f9dd=_0x53298b[_0xfe1df0(0x237)];else{if(_0xdbc537)_0x15f9dd=_0xfe1df0(0xf1);}return _0xfe1df0(0x267)+_0x15f9dd+_0xfe1df0(0x24e)+String['fromCharCode'](_0x53298b[_0xfe1df0(0x1f4)](0x41,_0x3a71fc))+_0xfe1df0(0x238)+_0x4a481f[_0xfe1df0(0x2cf)]+_0xfe1df0(0x1d5);})[_0x19d26e(0x259)]('');const _0x5611cd=_0x4a2e01[_0x19d26e(0x27a)]?_0x19d26e(0x30b)+_0x339e01+_0x19d26e(0x1dc)+_0x4a2e01[_0x19d26e(0x27a)]+_0x19d26e(0x2c6):'';let _0x168160='';if(_0x4a2e01[_0x19d26e(0x2bc)])_0x168160+=_0x19d26e(0x37d)+_0x4a2e01['explanation_audio_eng']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x4a2e01[_0x19d26e(0x2ac)])_0x168160+=_0x19d26e(0x15f)+_0x4a2e01[_0x19d26e(0x2ac)]+_0x19d26e(0x2f7);let _0x58d1e6=(_0x4a2e01[_0x19d26e(0x263)]||[])[_0x19d26e(0x32e)](_0x38df95=>_0x38df95?_0x19d26e(0x18b)+_0x38df95+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>':'')[_0x19d26e(0x259)]('');_0x4f656a[_0x19d26e(0x1b1)]=_0x19d26e(0xde)+_0x53298b['uWZRk'](_0x339e01,0x1)+_0x19d26e(0x32d)+(_0x53298b[_0x19d26e(0x15d)](_0x495f4e,_0x53298b[_0x19d26e(0x319)])?_0x53298b[_0x19d26e(0x363)]:_0x53298b[_0x19d26e(0x15d)](_0x495f4e,_0x53298b[_0x19d26e(0x21d)])?_0x53298b[_0x19d26e(0x357)]:_0x53298b['Vsgwv'])+_0x19d26e(0x197)+_0x597625+_0x19d26e(0x201)+_0x4a2e01[_0x19d26e(0x2cf)]+_0x19d26e(0x1f6)+_0x4bd407+_0x19d26e(0x173)+(_0x4a2e01[_0x19d26e(0xfd)]||_0x53298b[_0x19d26e(0x157)])+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x5611cd+_0x19d26e(0x1b3)+_0x168160+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x58d1e6+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>',_0x5f347d[_0x19d26e(0x2a7)](_0x4f656a);}),_0x53298b[_0x1c9703(0x31f)](initializeReviewVideos);}function initializeReviewVideos(){const _0x34de5b=_0x3b866c,_0x18b490={'RMGGO':_0x34de5b(0x162),'yVBoi':function(_0x5e2537,_0x530b59,_0x5efa89){return _0x5e2537(_0x530b59,_0x5efa89);},'DzxeZ':_0x34de5b(0x362)};document[_0x34de5b(0x2d3)](_0x18b490[_0x34de5b(0x291)])[_0x34de5b(0x218)](_0xe3e4bf=>{const _0x51dbe9=_0x34de5b,_0x17a4fb=_0xe3e4bf[_0x51dbe9(0x26e)]['src'];if(_0x17a4fb&&_0x17a4fb[_0x51dbe9(0x312)](_0x18b490['RMGGO']))_0x18b490['yVBoi'](setupVideo,_0xe3e4bf,_0x17a4fb);else _0x17a4fb&&(_0xe3e4bf[_0x51dbe9(0xe4)]=_0x17a4fb);});}function retakeQuiz(){const _0x17a234=_0x3b866c,_0x11448e={'LpqNV':function(_0x7f9af6,_0x24138b){return _0x7f9af6===_0x24138b;},'YSRbS':'timed_exam','zGZGQ':'statsBar','xXzLq':_0x17a234(0x2a3),'FqsOR':_0x17a234(0x1b4),'wWMtG':_0x17a234(0x2a6),'WEtFo':_0x17a234(0x2f0),'VNCIK':function(_0xd11e07,_0x4984e9){return _0xd11e07===_0x4984e9;},'hKGRn':_0x17a234(0x280),'UgqHh':_0x17a234(0x328),'SdAwl':function(_0x541933,_0x180d49){return _0x541933(_0x180d49);},'RDmtP':function(_0x37e09c,_0x5215b8){return _0x37e09c>=_0x5215b8;},'knReR':function(_0x35a255,_0x2728f9){return _0x35a255<_0x2728f9;},'JRfUs':function(_0x49274f){return _0x49274f();},'AcVfu':function(_0x549ef2){return _0x549ef2();},'bYBMX':function(_0x35e60e,_0x5a97dc){return _0x35e60e(_0x5a97dc);},'wVBwm':_0x17a234(0x32a),'BcSxC':_0x17a234(0x21b)};if(_0x11448e[_0x17a234(0x29b)](confirm,_0x11448e[_0x17a234(0x298)])){if(_0x11448e['LpqNV'](_0x17a234(0x17e),_0x11448e[_0x17a234(0x347)])){_0x22b75c=_0x452b65[_0x17a234(0x2cd)]();const _0xf3171d=_0x28d98f[_0x17a234(0x23e)](_0x17a234(0x1bc)),_0x50f43a=_0x474bbb[_0x17a234(0x23e)]('markReviewBtn'),_0x158715=_0x21a1aa['getElementById'](_0x17a234(0x226)),_0x4ad7cf=_0x5f1761===_0x17a234(0x35d)||_0x11448e[_0x17a234(0x2d9)](_0x3850b0,_0x11448e['YSRbS']);_0x14b7ba[_0x17a234(0x23e)](_0x11448e[_0x17a234(0x271)])['style'][_0x17a234(0x1af)]=_0x4ad7cf?_0x11448e[_0x17a234(0x2fc)]:_0x11448e[_0x17a234(0x2b0)],_0x53d126[_0x17a234(0x23e)](_0x11448e[_0x17a234(0x1a8)])['style'][_0x17a234(0x1af)]=_0x4ad7cf?_0x17a234(0x2a3):'block',_0x3f6029[_0x17a234(0x23e)](_0x17a234(0xfb))[_0x17a234(0xf8)][_0x17a234(0x1af)]=_0x4ad7cf?_0x17a234(0x1b4):_0x17a234(0x2a3),_0x5d41b9['getElementById'](_0x17a234(0x212))[_0x17a234(0xf8)]['display']=_0x4ad7cf?_0x17a234(0x1b4):_0x11448e[_0x17a234(0x2fc)],_0xf3171d[_0x17a234(0xf8)][_0x17a234(0x1af)]=_0x4ad7cf?_0x11448e[_0x17a234(0x2fc)]:_0x17a234(0x2f0),_0x50f43a[_0x17a234(0xf8)]['display']=_0x4ad7cf?_0x11448e[_0x17a234(0x2cc)]:_0x17a234(0x2a3),_0x158715['style'][_0x17a234(0x1af)]=_0x4ad7cf?_0x11448e['WEtFo']:_0x11448e[_0x17a234(0x2fc)],(_0x11448e[_0x17a234(0x2d9)](_0x177714,'timed_study')||_0x11448e[_0x17a234(0x143)](_0x42fa8e,_0x11448e['YSRbS']))&&_0x589e28[_0x17a234(0x23e)](_0x11448e[_0x17a234(0x327)])[_0x17a234(0x1dd)][_0x17a234(0x2e6)](_0x11448e[_0x17a234(0x178)]),!_0x11448e['SdAwl'](_0x56a69e,_0x1aefae)&&_0x11448e[_0x17a234(0x15e)](_0x4ecb64,0x0)&&_0x11448e['knReR'](_0x2def61,_0x46c786[_0x17a234(0x1b5)])&&(_0x4685ff=_0x263b97),_0x11448e['JRfUs'](_0x1260e2),_0x11448e[_0x17a234(0x1f7)](_0x49cacd),_0x11448e[_0x17a234(0x1f7)](_0x1f62ba),_0x11448e['AcVfu'](_0x29e922);}else window[_0x17a234(0x1bd)][_0x17a234(0x2c7)][_0x17a234(0xdc)]('custom_quiz.html')&&localStorage[_0x17a234(0x1fd)](_0x17a234(0x196)),clearProgress(),location['reload']();}}function loadBookmarkedQuestions(){const _0x248f52=_0x3b866c,_0x500798={'Mzwlm':_0x248f52(0x1d2),'mSbfu':'totalAttempted','QaIMU':function(_0xd7951,_0x122528){return _0xd7951*_0x122528;},'iodti':function(_0x2cd7a2,_0x594237){return _0x2cd7a2/_0x594237;},'BievT':function(_0x43f73d,_0x476d66){return _0x43f73d+_0x476d66;},'ZbKOZ':function(_0x3dc970,_0x5c933c){return _0x3dc970/_0x5c933c;},'BnBUp':function(_0x1de895,_0x4a4e64){return _0x1de895/_0x4a4e64;},'VNfuc':function(_0x1f6b0f,_0x327d4b){return _0x1f6b0f!==_0x327d4b;},'RlELx':'gzfMJ','PcgdQ':function(_0x38e382,_0x1e587e){return _0x38e382===_0x1e587e;},'LIsVW':'QPdSB','DvKsK':'bookmarkedQuestions'},_0x2858c8=JSON[_0x248f52(0x31e)](localStorage['getItem'](_0x500798[_0x248f52(0x167)]))||[];_0x2858c8[_0x248f52(0x218)](_0x15e7ba=>{const _0x1ec07a=_0x248f52,_0x74e96={'QyPFZ':'timerContainer'};if(_0x500798['VNfuc'](_0x500798[_0x1ec07a(0x139)],_0x1ec07a(0x1ca)))_0x15e7ba[_0x1ec07a(0x228)][_0x1ec07a(0x312)](quizName[_0x1ec07a(0x1bf)]()[_0x1ec07a(0x255)](/ /g,'-'))&&(_0x500798[_0x1ec07a(0x1c1)](_0x1ec07a(0x179),_0x500798[_0x1ec07a(0x2d2)])?_0x595775[_0x1ec07a(0x23e)](_0x74e96[_0x1ec07a(0x2d4)])[_0x1ec07a(0x1dd)]['remove'](_0x1ec07a(0x328)):_0x15e7ba['questionIndex']<questionsData[_0x1ec07a(0x1b5)]&&(questionStates[_0x15e7ba['questionIndex']][_0x1ec07a(0x320)]=!![]));else{_0xb9d863[_0x1ec07a(0x23e)](_0x500798[_0x1ec07a(0x232)])[_0x1ec07a(0x343)]=_0x3c1114[_0x1ec07a(0x17f)],_0x3f7061[_0x1ec07a(0x23e)](_0x1ec07a(0x2b1))[_0x1ec07a(0x343)]=_0x464b32[_0x1ec07a(0x35a)],_0x5c064b[_0x1ec07a(0x23e)](_0x500798['mSbfu'])['textContent']=_0x30e8fa[_0x1ec07a(0x234)];const _0x4538b0=_0x3f77da[_0x1ec07a(0x234)]>0x0?_0x2c3b51[_0x1ec07a(0x2d5)](_0x500798[_0x1ec07a(0x10e)](_0x500798['iodti'](_0x76a191[_0x1ec07a(0x17f)],_0x34037d[_0x1ec07a(0x234)]),0x64)):0x0;_0x302e12[_0x1ec07a(0x23e)]('accuracy')[_0x1ec07a(0x343)]=_0x500798['BievT'](_0x4538b0,'%'),_0x2bce91[_0x1ec07a(0x368)]=_0x870db0[_0x1ec07a(0x34a)]((_0x47b1cd,_0xd73108)=>_0x47b1cd+_0xd73108[_0x1ec07a(0x1a9)],0x0);const _0x526bb2=_0x14770a[_0x1ec07a(0x160)](_0x500798[_0x1ec07a(0x1d1)](_0x1475d1[_0x1ec07a(0x368)],0x3e8)),_0x32a3b0=_0x824e32[_0x1ec07a(0x160)](_0x500798[_0x1ec07a(0x1b2)](_0x526bb2,0x3c)),_0x45df65=_0x526bb2%0x3c;_0x1c64a5[_0x1ec07a(0x23e)](_0x1ec07a(0x1a9))['textContent']=_0x500798[_0x1ec07a(0x332)](_0x500798[_0x1ec07a(0x332)](_0x32a3b0,':'),_0x45df65[_0x1ec07a(0x12c)]()[_0x1ec07a(0x192)](0x2,'0'));}});}function toggleBookmark(){const _0x124950=_0x3b866c,_0x3895f5={'ujnUl':_0x124950(0x1ef),'vxTLY':_0x124950(0xe2),'zVTSA':function(_0xbaa34f){return _0xbaa34f();}},_0x11be3a=!questionStates[currentQuestionIndex][_0x124950(0x320)];questionStates[currentQuestionIndex]['bookmarked']=_0x11be3a;let _0x52dbc8=JSON[_0x124950(0x31e)](localStorage[_0x124950(0x124)](_0x3895f5[_0x124950(0xef)]))||[];if(_0x11be3a){if(_0x3895f5[_0x124950(0x2d7)]===_0x3895f5[_0x124950(0x2d7)]){const _0x5a5cad={'quizName':quizName,'quizFile':window[_0x124950(0x1bd)][_0x124950(0x2c7)][_0x124950(0x21f)]('/')[_0x124950(0x274)](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x124950(0x2cd)]()};_0x52dbc8['push'](_0x5a5cad);}else{const _0xd2e075={'quizName':_0x88dc2f,'quizFile':_0x127c90[_0x124950(0x1bd)]['pathname'][_0x124950(0x21f)]('/')[_0x124950(0x274)](),'questionIndex':_0xdc6ebe,'question':_0x1e5c89[_0x1e95d7],'hierarchy':_0x13421c,'timestamp':_0x1d0484[_0x124950(0x2cd)]()};_0x1e3b30[_0x124950(0x345)](_0xd2e075);}}else _0x52dbc8=_0x52dbc8['filter'](_0x1a79f6=>!(_0x1a79f6[_0x124950(0x228)]['includes'](quizName[_0x124950(0x1bf)]()[_0x124950(0x255)](/ /g,'-'))&&_0x1a79f6[_0x124950(0x27c)]===currentQuestionIndex));localStorage[_0x124950(0x303)](_0x3895f5[_0x124950(0xef)],JSON[_0x124950(0x17b)](_0x52dbc8)),_0x3895f5[_0x124950(0x282)](updateBookmarkButton),_0x3895f5[_0x124950(0x282)](updateQuestionNav);}function updateBookmarkButton(){const _0x3316c5=_0x3b866c,_0x50c7af={'cuGCT':'bookmarkText','RuSez':_0x3316c5(0x141),'hIgTr':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','OHlpA':_0x3316c5(0x292),'PHvfQ':_0x3316c5(0x1e2)},_0x2ec8cb=document[_0x3316c5(0x23e)](_0x3316c5(0x1bc)),_0x24c230=document['getElementById'](_0x50c7af['cuGCT']),_0x21c16e=questionStates[currentQuestionIndex][_0x3316c5(0x320)];_0x2ec8cb[_0x3316c5(0x300)]=_0x21c16e?_0x50c7af[_0x3316c5(0x2c5)]:_0x50c7af[_0x3316c5(0x142)],_0x24c230[_0x3316c5(0x343)]=_0x21c16e?_0x50c7af[_0x3316c5(0x2fd)]:_0x50c7af[_0x3316c5(0x17d)];}function toggleMarkForReview(){const _0x2d3e9a=_0x3b866c,_0xe8d503={'AoqeJ':function(_0x288e3e){return _0x288e3e();},'TCHtx':function(_0x27fa1d){return _0x27fa1d();}};questionStates[currentQuestionIndex]['markedForReview']=!questionStates[currentQuestionIndex][_0x2d3e9a(0x29c)],_0xe8d503[_0x2d3e9a(0x2b6)](updateMarkReviewButton),_0xe8d503['TCHtx'](updateQuestionNav);}function updateMarkReviewButton(){const _0x2c1066=_0x3b866c,_0x486893={'svPok':_0x2c1066(0x21a),'ukfQX':_0x2c1066(0x378),'lQsGO':_0x2c1066(0x1fb),'TZhUE':_0x2c1066(0x385),'Pbrvz':_0x2c1066(0x308)},_0x398074=document[_0x2c1066(0x23e)]('markReviewBtn'),_0x234811=document['getElementById'](_0x486893[_0x2c1066(0x2f6)]),_0x281f3a=questionStates[currentQuestionIndex][_0x2c1066(0x29c)];_0x398074[_0x2c1066(0x300)]=_0x281f3a?_0x486893[_0x2c1066(0x123)]:_0x486893[_0x2c1066(0x30d)],_0x234811['textContent']=_0x281f3a?_0x486893['TZhUE']:_0x486893[_0x2c1066(0x31c)];}function previousQuestion(){const _0x548413=_0x3b866c,_0x237ea5={'trSgh':function(_0x283b95,_0x3e2d1f){return _0x283b95>_0x3e2d1f;},'TVQMS':function(_0x40dcaf,_0x5182f5){return _0x40dcaf-_0x5182f5;},'WPhrO':function(_0x678158){return _0x678158();}};_0x237ea5[_0x548413(0x14d)](currentQuestionIndex,0x0)&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x548413(0x1a9)]+=_0x237ea5['TVQMS'](Date[_0x548413(0x2cd)](),questionStartTime)),currentQuestionIndex--,_0x237ea5[_0x548413(0x23f)](displayQuestion),saveProgress());}function nextQuestion(){const _0x156f64=_0x3b866c,_0x47421e={'vLBIX':function(_0x2a79c9,_0x2d791a){return _0x2a79c9-_0x2d791a;},'PSbxo':_0x156f64(0x2fb),'bdoTD':function(_0x42c0d7,_0x4d297b){return _0x42c0d7<_0x4d297b;},'ojThJ':_0x156f64(0x27b),'tFBDN':_0x156f64(0x354),'Fwmlh':function(_0xc3d959){return _0xc3d959();},'Zgkda':function(_0x5a0740,_0x47d092){return _0x5a0740<_0x47d092;},'OCCJM':function(_0x2c5082,_0x68f09a){return _0x2c5082-_0x68f09a;},'zgwQI':'ETPZI','fmnzV':function(_0x47f591){return _0x47f591();},'yXKfL':function(_0x28ae4a,_0x507900){return _0x28ae4a===_0x507900;},'gaOMH':_0x156f64(0x158),'MIOTW':function(_0x164c38,_0x82b52b){return _0x164c38===_0x82b52b;},'whqPa':_0x156f64(0x35d),'FcAXt':_0x156f64(0x1ac),'wimtI':function(_0x3a6181,_0xb6fb01){return _0x3a6181(_0xb6fb01);},'PYXUJ':_0x156f64(0xe0),'dHrtW':function(_0x114b31){return _0x114b31();},'SFTtD':_0x156f64(0x26d),'TqPqp':function(_0xa76f4c){return _0xa76f4c();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x156f64(0x1a9)]+=_0x47421e[_0x156f64(0x22a)](Date[_0x156f64(0x2cd)](),questionStartTime));if(_0x47421e['Zgkda'](currentQuestionIndex,_0x47421e[_0x156f64(0x1a7)](questionsData[_0x156f64(0x1b5)],0x1)))_0x156f64(0x2b8)===_0x47421e[_0x156f64(0x1eb)]?(currentQuestionIndex++,_0x47421e[_0x156f64(0x1b9)](displayQuestion),_0x47421e[_0x156f64(0x28d)](saveProgress)):_0x363dda[_0x3ec454][_0x156f64(0x1a9)]+=_0x47421e[_0x156f64(0x22a)](_0x48c97c[_0x156f64(0x2cd)](),_0x23d919);else{if(_0x47421e[_0x156f64(0x262)](_0x47421e[_0x156f64(0x17a)],'dDbus'))_0x47421e[_0x156f64(0x119)](currentMode,_0x47421e[_0x156f64(0x229)])||_0x47421e[_0x156f64(0x119)](currentMode,_0x47421e[_0x156f64(0x2e3)])?_0x47421e[_0x156f64(0x311)](confirm,_0x47421e[_0x156f64(0x36f)])&&_0x47421e[_0x156f64(0x266)](submitQuiz):confirm(_0x47421e[_0x156f64(0x33d)])&&(currentQuestionIndex=0x0,_0x47421e[_0x156f64(0x2a4)](displayQuestion),_0x47421e['Fwmlh'](saveProgress));else{const _0x3df81b=_0x5c1bed[_0x156f64(0x23e)](_0x47421e[_0x156f64(0x10f)]);_0x3df81b[_0x156f64(0x1b1)]='';for(let _0x56e6bc=0x0;_0x47421e['bdoTD'](_0x56e6bc,_0x409008[_0x156f64(0x1b5)]);_0x56e6bc++){const _0xc29940=_0x3fbe12[_0x156f64(0x2b2)](_0x47421e[_0x156f64(0x230)]);_0xc29940[_0x156f64(0x343)]=_0x56e6bc+0x1,_0xc29940['className']=_0x47421e[_0x156f64(0x174)],_0xc29940[_0x156f64(0x278)]=()=>_0x389d1d(_0x56e6bc),_0xc29940['id']=_0x156f64(0x241)+_0x56e6bc,_0x3df81b['appendChild'](_0xc29940);}_0x47421e[_0x156f64(0x28d)](_0x12e080);}}}function startTimer(){const _0x2bb48d=_0x3b866c,_0xc17dae={'nIHIB':function(_0x1d9704,_0x24c330){return _0x1d9704<_0x24c330;},'BwKrV':'correct','WugOx':function(_0x3c883f){return _0x3c883f();},'CcGpR':function(_0x2e6372,_0x3127bf){return _0x2e6372<=_0x3127bf;},'hHAiH':_0x2bb48d(0x2ef),'wKhLz':function(_0x1374fc,_0x2e5283){return _0x1374fc===_0x2e5283;},'DCmOa':function(_0x2d8f0b,_0x4a0b8e){return _0x2d8f0b===_0x4a0b8e;},'HJWZE':'FLFso','zdKqY':'eSWWt','uKFFp':function(_0x493e0a){return _0x493e0a();},'QLina':function(_0x3f2fbb,_0x5e72ca){return _0x3f2fbb!==_0x5e72ca;},'JJIqf':_0x2bb48d(0x186),'OjypI':function(_0x2668e6,_0x4eadea){return _0x2668e6(_0x4eadea);},'ALfzB':function(_0x54ae85){return _0x54ae85();},'caqDy':function(_0x124850,_0x416580,_0x4fac87){return _0x124850(_0x416580,_0x4fac87);}};if(timer)_0xc17dae['OjypI'](clearInterval,timer);timeRemaining=0x78,_0xc17dae['ALfzB'](updateTimerDisplay),timer=_0xc17dae[_0x2bb48d(0x148)](setInterval,()=>{const _0x5dab61=_0x2bb48d,_0x161291={'qjwaz':function(_0x1e444f,_0x18ed9b){const _0x5058f5=_0x877c;return _0xc17dae[_0x5058f5(0x323)](_0x1e444f,_0x18ed9b);},'rTDVf':_0xc17dae[_0x5dab61(0x207)]};timeRemaining--,_0xc17dae[_0x5dab61(0x1e5)](updateTimerDisplay),_0xc17dae[_0x5dab61(0x204)](timeRemaining,0x0)&&(_0xc17dae[_0x5dab61(0x251)]===_0xc17dae['hHAiH']?(clearInterval(timer),_0xc17dae[_0x5dab61(0x375)](currentMode,_0x5dab61(0x1ac))?_0xc17dae[_0x5dab61(0x183)](_0xc17dae[_0x5dab61(0x131)],_0xc17dae[_0x5dab61(0x36d)])?_0x5c3869[_0x5dab61(0x228)]['includes'](_0x3980cb[_0x5dab61(0x1bf)]()[_0x5dab61(0x255)](/ /g,'-'))&&(_0x161291[_0x5dab61(0x2c4)](_0x3e81ce[_0x5dab61(0x27c)],_0x1d60f4['length'])&&(_0x14ff09[_0x3dafc1['questionIndex']]['bookmarked']=!![])):_0xc17dae[_0x5dab61(0x2ab)](submitQuiz):_0xc17dae[_0x5dab61(0x1f3)](_0xc17dae[_0x5dab61(0x2c0)],_0x5dab61(0x186))?(_0x4d6ff3++,_0x3f9e48(),_0x1e494a()):_0xc17dae['uKFFp'](nextQuestion)):(_0x191961=_0x161291[_0x5dab61(0x33a)],_0x273900='Correct'));},0x3e8);}function updateTimerDisplay(){const _0x2d73b4=_0x3b866c,_0x55dbf3={'nstqe':function(_0x16d4ad,_0x34e382){return _0x16d4ad/_0x34e382;},'hxsyi':function(_0x540eb2,_0x263241){return _0x540eb2%_0x263241;},'WqqnA':'timeDisplay','NPEck':function(_0x43b719,_0xcc0dc4){return _0x43b719+_0xcc0dc4;},'kJWdn':function(_0x504562,_0x5c2003){return _0x504562+_0x5c2003;}},_0x26a8d7=Math[_0x2d73b4(0x160)](_0x55dbf3[_0x2d73b4(0x210)](timeRemaining,0x3c)),_0x16ec27=_0x55dbf3[_0x2d73b4(0x372)](timeRemaining,0x3c);document[_0x2d73b4(0x23e)](_0x55dbf3[_0x2d73b4(0xd3)])['textContent']=_0x55dbf3[_0x2d73b4(0x360)](_0x55dbf3[_0x2d73b4(0x2ee)](_0x26a8d7,':'),_0x16ec27[_0x2d73b4(0x12c)]()['padStart'](0x2,'0'));}function toggleSidebar(){const _0x1faf99=_0x3b866c,_0x403b7b={'tKkwK':_0x1faf99(0x194),'wIqBE':_0x1faf99(0x2a1)};document[_0x1faf99(0x23e)](_0x403b7b[_0x1faf99(0x28b)])['classList']['toggle'](_0x403b7b[_0x1faf99(0x219)]);}document[_0x3b866c(0x1fa)](_0x3b866c(0x176),()=>{const _0x29c3ae=_0x3b866c,_0x874d10={'xDMWS':_0x29c3ae(0x265),'YTJZj':_0x29c3ae(0x15a),'Rlhlx':function(_0x41434a,_0x555e03){return _0x41434a!==_0x555e03;},'Sytzh':_0x29c3ae(0x111),'AKVCi':function(_0x3168b6){return _0x3168b6();},'EtWsc':function(_0x26faf5){return _0x26faf5();},'dASxx':_0x29c3ae(0x220),'BfWbl':_0x29c3ae(0x2f0),'iqTzZ':_0x29c3ae(0x109),'FMaYe':_0x29c3ae(0x32b),'RaqRL':function(_0x35ba3c){return _0x35ba3c();}};if(resume)_0x874d10[_0x29c3ae(0x25f)](_0x874d10[_0x29c3ae(0x272)],'hNrBQ')?_0x874d10[_0x29c3ae(0x2a8)](loadProgress)?(document[_0x29c3ae(0x23e)](_0x29c3ae(0x220))[_0x29c3ae(0xf8)][_0x29c3ae(0x1af)]=_0x29c3ae(0x2a3),_0x874d10['EtWsc'](initializeQuiz)):(_0x874d10['AKVCi'](clearProgress),document[_0x29c3ae(0x23e)](_0x874d10[_0x29c3ae(0x2e0)])[_0x29c3ae(0xf8)][_0x29c3ae(0x1af)]=_0x874d10[_0x29c3ae(0x307)]):_0x3c274b=_0x367290;else!window[_0x29c3ae(0x1bd)][_0x29c3ae(0x2c7)][_0x29c3ae(0xdc)](_0x29c3ae(0x190))?(_0x874d10[_0x29c3ae(0x208)](clearProgress),document[_0x29c3ae(0x23e)]('modeModal')['style'][_0x29c3ae(0x1af)]=_0x874d10[_0x29c3ae(0x307)]):_0x874d10[_0x29c3ae(0x253)]===_0x874d10[_0x29c3ae(0x101)]?(_0x1014b1=_0x874d10[_0x29c3ae(0x221)],_0x2edcae=_0x874d10['YTJZj']):_0x874d10[_0x29c3ae(0x242)](initializeQuiz);}),document[_0x3b866c(0x1fa)]('keydown',function(_0x478963){const _0x32bdee=_0x3b866c,_0x30f9db={'FknpN':function(_0x11bfd7,_0x54b020){return _0x11bfd7===_0x54b020;},'ZanTy':_0x32bdee(0x26f),'gEVQu':_0x32bdee(0x164),'umTUf':_0x32bdee(0xf1),'bsNuS':_0x32bdee(0x296),'yUnff':'Previous\x20progress\x20cleared.','rAGTY':function(_0x2f8907){return _0x2f8907();},'jwxGm':_0x32bdee(0x220),'WwmGs':_0x32bdee(0x2a3),'kWvoc':_0x32bdee(0x350),'AdMKa':'hidden','HmVTi':function(_0x211720,_0x5c564a){return _0x211720<=_0x5c564a;},'QGKZZ':function(_0x499faa,_0x7c81b6){return _0x499faa!==_0x7c81b6;},'GkjRn':'yJMNw','JDnZm':_0x32bdee(0x270),'VlZeu':function(_0x545d2e,_0xaa1673){return _0x545d2e-_0xaa1673;},'pfgqk':function(_0x2b4ec1,_0x49837f){return _0x2b4ec1(_0x49837f);},'oBAjc':'.option-button','sSPhk':function(_0x3caa3c,_0x11ba59){return _0x3caa3c<_0x11ba59;},'jJxJI':_0x32bdee(0x155),'uiYiE':_0x32bdee(0x231),'QkSue':function(_0x30b4f2,_0x2fd5e0){return _0x30b4f2===_0x2fd5e0;},'edVvH':_0x32bdee(0x2af),'wXFqG':function(_0x1dca61,_0x153666){return _0x1dca61!==_0x153666;},'BBrDn':_0x32bdee(0x250),'ATjXU':'UlCMM','xkLdL':function(_0x2c9131){return _0x2c9131();},'Qplcj':function(_0x5eadf0,_0x37f11e){return _0x5eadf0===_0x37f11e;},'ciKzh':function(_0x237613,_0x1d1cdc){return _0x237613===_0x1d1cdc;},'YUelE':_0x32bdee(0x1ac),'RDInl':function(_0x1657a8,_0xad9233){return _0x1657a8===_0xad9233;},'XSTgj':'odaTk','KPOYK':function(_0x2a224c){return _0x2a224c();},'pdtPf':function(_0x3a16bb,_0x43a05e){return _0x3a16bb===_0x43a05e;},'OwozJ':function(_0x4f007a,_0x21d58c){return _0x4f007a===_0x21d58c;},'ZPfor':function(_0x225911,_0x16868d){return _0x225911!==_0x16868d;},'pXtqK':'UaGXo','PVJzU':'kRfFG','ydyEM':function(_0x4f34ca){return _0x4f34ca();}};if(document[_0x32bdee(0x23e)](_0x30f9db['jwxGm'])['style'][_0x32bdee(0x1af)]!==_0x30f9db['WwmGs'])return;if(_0x30f9db[_0x32bdee(0x348)](document[_0x32bdee(0x23e)](_0x30f9db[_0x32bdee(0x386)])[_0x32bdee(0x1dd)][_0x32bdee(0x110)](_0x30f9db['AdMKa']),![]))return;if(_0x478963['key']>='1'&&_0x30f9db[_0x32bdee(0x2ea)](_0x478963[_0x32bdee(0x1a5)],'4')){if(_0x30f9db[_0x32bdee(0x1c2)](_0x30f9db[_0x32bdee(0x18c)],_0x30f9db[_0x32bdee(0x18f)])){const _0x4b53a1=_0x30f9db[_0x32bdee(0x22d)](_0x30f9db[_0x32bdee(0x302)](parseInt,_0x478963[_0x32bdee(0x1a5)]),0x1),_0x165e46=document[_0x32bdee(0x2d3)](_0x30f9db[_0x32bdee(0x182)]);if(_0x30f9db[_0x32bdee(0x128)](_0x4b53a1,_0x165e46['length']))_0x30f9db['pfgqk'](selectOption,_0x4b53a1);}else{const _0x50dd85=_0x28172d[_0x32bdee(0x205)]===_0x129dd9,_0x3b8416=_0x30f9db['FknpN'](_0x48ab96['id'],_0x1fd08d);let _0x4f73dd=_0x30f9db[_0x32bdee(0x314)];if(_0x3b8416)_0x4f73dd=_0x30f9db['gEVQu'];else{if(_0x50dd85)_0x4f73dd=_0x30f9db[_0x32bdee(0x28a)];}return _0x32bdee(0x267)+_0x4f73dd+_0x32bdee(0x24e)+_0x5c20a6[_0x32bdee(0x275)](0x41+_0x17470f)+_0x32bdee(0x238)+_0x37c667[_0x32bdee(0x2cf)]+_0x32bdee(0x1d5);}}else{if(_0x30f9db['FknpN'](_0x478963[_0x32bdee(0x1a5)],_0x30f9db[_0x32bdee(0x2d8)]))_0x30f9db['rAGTY'](previousQuestion);else{if(_0x30f9db[_0x32bdee(0x348)](_0x478963[_0x32bdee(0x1a5)],_0x32bdee(0x2ca))||_0x478963['key']==='\x20'){if(_0x30f9db['uiYiE']!==_0x32bdee(0x1a0))_0x478963[_0x32bdee(0x150)](),nextQuestion();else{const _0x2ec776=_0x3f1aa2[_0x32bdee(0x31e)](_0x2468e6[_0x32bdee(0x124)](_0x32bdee(0x296)))||{};_0x2ec776[_0x2c2f4b]&&(delete _0x2ec776[_0x55c271],_0x52d56c[_0x32bdee(0x303)](_0x30f9db[_0x32bdee(0x33c)],_0x373812['stringify'](_0x2ec776)),_0x4868f8[_0x32bdee(0x371)](_0x30f9db[_0x32bdee(0x284)]));}}else{if(_0x30f9db[_0x32bdee(0x118)](_0x478963[_0x32bdee(0x1a5)][_0x32bdee(0x1bf)](),'b')&&(currentMode===_0x32bdee(0x100)||currentMode===_0x30f9db[_0x32bdee(0xf2)])){if(_0x30f9db[_0x32bdee(0x293)](_0x30f9db[_0x32bdee(0x121)],_0x30f9db['ATjXU']))_0x30f9db[_0x32bdee(0xfa)](toggleBookmark);else{const _0x134b13=_0x1e643b?function(){const _0x30d7d0=_0x32bdee;if(_0x5bfcdb){const _0x3f2e61=_0x4f5aa0[_0x30d7d0(0x16e)](_0x31d75c,arguments);return _0x2915c7=null,_0x3f2e61;}}:function(){};return _0x2d3b13=![],_0x134b13;}}else{if(_0x30f9db[_0x32bdee(0x348)](_0x478963[_0x32bdee(0x1a5)][_0x32bdee(0x1bf)](),'m')&&(_0x30f9db[_0x32bdee(0x31a)](currentMode,_0x32bdee(0x35d))||_0x30f9db['ciKzh'](currentMode,_0x30f9db[_0x32bdee(0x1b0)])))_0x30f9db['RDInl']('OcYIc',_0x30f9db['XSTgj'])?(_0x4c7e01[_0x3818aa][_0x32bdee(0x29c)]=!_0x250a92[_0x15bb5c][_0x32bdee(0x29c)],_0x30f9db['rAGTY'](_0x1a4785),_0xf5336c()):_0x30f9db['KPOYK'](toggleMarkForReview);else _0x30f9db[_0x32bdee(0xdb)](_0x478963[_0x32bdee(0x1a5)][_0x32bdee(0x1bf)](),'s')&&(_0x30f9db[_0x32bdee(0x2eb)](currentMode,'test')||_0x30f9db['FknpN'](currentMode,_0x30f9db['YUelE']))&&(_0x30f9db[_0x32bdee(0x33b)](_0x30f9db[_0x32bdee(0x24c)],_0x30f9db[_0x32bdee(0x260)])?_0x30f9db[_0x32bdee(0x34d)](submitQuiz):_0x58df57=_0x29ac99);}}}}});</script>

</body></html>